Document:

Exhibit 10.12

 

CONFIDENTIAL

 

EXCLUSIVE LICENSE AGREEMENT

 

by and between

 

Anthony C. Forster, M.D., Ph.D.
 an individual

 

and

 

Ra Pharmaceuticals, Inc.
 a Delaware corporation

 

 

EXCLUSIVE LICENSE AGREEMENT

 

Version of 2010/10/18

 

This Exclusive License Agreement (this “Agreement”) is effective as of November 29, 2010 (the “Effective Date”), by and between Anthony C. Forster, M.D., Ph.D., an individual located at 357 Childe Harold’s Circle, Brentwood, TN 37027 (“Forster”), and Ra Pharmaceuticals, Inc., a Delaware corporation located at 222 Berkeley Street, 20th Floor, Boston MA 02116 (“Ra”). Forster and Ra are each sometimes referred to herein as a “Party” or collectively as the “Parties.”

 

RECITALS

 

WHEREAS, Forster is the owner of certain Patent Rights and has the exclusive right to grant licenses under said Patent Rights, subject only to (i) a royalty-free, irrevocable, nonexclusive, license to practice the inventions claimed in the Patent Rights for or on behalf of United States throughout the world; and (ii) The Brigham and Women’s Hospital, Inc.’s continuing right to use any invention described and/or claimed in the Patent Rights for clinical, educational and research purposes;

 

WHEREAS, Forster has an obligation to pay a portion of all consideration received under this Agreement to Dr. Stephen C. Blacklow (“Blacklow”) as required under certain Assignment, dated November 17, 2000 (the “Blacklow Assignment”), pursuant to which Blacklow assigned all of Blacklow’s rights under the Patent Rights to Forster;

 

WHEREAS, Forster and Ra entered into that certain Exclusive Option Letter Agreement, dated July 13, 2009 (the “Option Agreement”), pursuant to which Forster granted Ra an exclusive first option to enter into a worldwide, exclusive license to Forster’s interest in the Patent Rights (the “Option”); and

 

WHEREAS, Ra has exercised the Option and desires to obtain the exclusive license under the Patent Rights upon the terms and conditions set forth in this Agreement, and Forster is willing to grant a license thereunder.

 

NOW, THEREFORE, in consideration of the foregoing premises, Forster and Ra hereby agree as follows:

 

ARTICLE 1
 DEFINITIONS

 

1.1                               “Affiliate” shall mean any entity which directly or indirectly controls, or is controlled by, or is under common control with, Ra. The term “control” as used herein means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors; or (b) with the power to direct the management and policies of such entities.

 

1.2                               “Combination Product” shall mean any Licensed Product sold or used in combination with one or more other products or processes which are not Licensed Products.

 

1.3                               “Field” shall mean all fields.

 

1.4                               “Licensed Processes” shall mean the processes claimed by Valid Claims in the Patent Rights.

 

1.5                               “Licensed Product” shall mean (i) any product the import, manufacture, use, offer for sale or sale of which, but for the licenses granted herein, would infringe a Valid Claim of the Patent Rights or (ii) any product made or used in accordance with or by means of Licensed Processes.

 

 

1.6                               “Net Sales” shall mean the gross amount billed or invoiced by Ra and its Affiliates and Sublicensees for sales or other transfers of Licensed Product to a final customer who shall be an end user of the Licensed Product, less the following:

 

(a)                                 customary trade, quantity, or cash discounts to the extent actually allowed and taken;

 

(b)                                 amounts repaid or credited by reason of rejection or return;

 

(c)                                  to the extent separately stated on purchase orders, invoices, or other documents of sale, any taxes and/or other governmental charges levied on the production, sale, transportation, delivery or use of a Licensed Product which is paid by or on behalf of Ra; and

 

(d)                                 outbound transportation costs prepaid or allowed and costs of insurance in transit.

 

For the avoidance of doubt, transfers of a Licensed Product between any of Ra, an Affiliate or a Sublicensee for sale by the transferee shall not be considered Net Sales hereunder.

 

In the event that a Licensed Product is sold as a Combination Product, Net Sales, for the purposes of determining royalty payments on the Combination Product, shall mean the gross amount collected for the Combination Product less the deductions set forth in clauses (a) - (d) above, multiplied by a proration factor that is determined as follows:

 

(i)                                     If all components of the Combination Product were sold separately during the same or immediately preceding calendar year, the proration factor shall be determined In the formula [A / (A+B)], where A is the average gross sales price of all Licensed Product components (as applicable) during such period when sold separately from the other component(s), and B is the average gross sales price of the other component(s) during such period when sold separately from the Licensed Product components (as applicable); or

 

(ii)                                  If all components of the Combination Product were not sold or provided separately during the same or immediately preceding calendar year, the proration factor shall be determined by the Parties in good faith negotiations based on the relative value contributed by each component.

 

1.7                               “Patent Rights” shall mean:

 

(a)                                 the United States and international patents listed on Exhibit A;

 

(b)                                 the Canadian and Japanese patent applications listed on Exhibit A;

 

(c)                                  any divisionals, continuations, and continued prosecution applications (or their relevant international equivalents) of the Canadian and Japanese patent applications listed on Exhibit A the extent the claims are directed to subject matter specifically described in the Canadian and Japanese patent applications listed on Exhibit A, and the resulting patents; and

 

(d)                                 any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents, including, without limitation supplementary protection certificates) of the patents described in clauses (a), (b) and (c) above.

 

1.8                               “Sublicensee” shall mean any non-Affiliate sublicensee of the rights granted by Ra pursuant to Section 2.2.

 

1.9                               “Term” shall mean the term of this Agreement, which shall commence on the Effective Date and shall remain in effect until the expiration or abandonment of all issued patents and pending

 

2

 

patent applications with the Patent Rights, unless earlier terminated in accordance with the provisions of this Agreement.

 

1.10                        “Territory” shall mean worldwide

 

1.11                        “Valid Claim” shall mean (a) a claim of an issued and unexpired patent which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application that was filed and has been prosecuted in good faith and has not been (i) cancelled, withdrawn, abandoned or finally disallowed without the possibility of appeal or refiling of such application, or (ii) pending for more than twenty (20) years since such claim was first presented.

 

ARTICLE 2
 GRANT OF RIGHTS

 

2.1                               License Grants.

 

(a)                                 Subject to the terms and conditions of this Agreement. Forster hereby grants to Ra and its Affiliates, and Ra accepts subject to the terms and conditions hereof, for the Term an exclusive license, with the right to sublicense, under the Patent Rights, to make, have made. use. have used, sell, have sold, offer to sell, have offered for sale, import, have imported, develop and commercialize Licensed Products and to practice the Licensed Processes in the Field in the Territory.

 

(b)                                 Forster acknowledges and agrees that, during the Term, it shall not directly or indirectly grant any licenses or other rights inconsistent with this Section 2.1.

 

2.2                               Sublicenses. Ra shall have the right to grant sublicenses of the rights and licenses granted to Ra hereunder. Ra shall incorporate terms and conditions into its sublicense agreements sufficient to enable Ra to comply with this Agreement. Ra shall promptly furnish Forster with a fully signed photocopy of any sublicense agreement. Any such sublicense agreement shall provide that upon termination of this Agreement, that such sublicense agreement shall provide for termination or assignment to Forster at the option of Forster of Ra*s interest therein, except that, upon termination of this Agreement for any reason, provided that a Sublicensee is not in material breach of its sublicense, at such Sublicensee’s request, Forster shall grant to such Sublicensee license rights and terms equivalent to the sublicense rights and terms which Ra previously granted to such Sublicensee, provided that such Sublicensee agrees to make future payments under Sections 4. L 4.2, 4.4, 4.5 and 4.6 resulting from such license that Ra would have been obligated to make to Forster hereunder.

 

2.3                               Retained Rights.

 

(a)                                 Forster shall retain the non-exclusive, non-transferable right for itself to practice the Patent Rights for non-commercial research; provided that such right does not include the right to practice the Patent Rights on behalf of any commercial third party, Forster shall provide prompt written notice to Ra of any inventions that rely on the use or practice of the Patent Rights pursuant to this Section 2.3(a), provided that this does not jeopardize patent protection of the new invention or violate the policy of Forster’s current employer.

 

(b)                                 Ra acknowledges that the U.S. Government retains a world-w ide, nonexclusive, irrevocable, royalty-free license to practice or have practiced for or on behalf of the United States any government-funded invention claimed in any Patent Rights as set forth in 35 U.S.C. §§ 200 et seq., and the regulations promulgated (hereunder, as amended, or any successor

 

3

 

statutes or regulations. All rights reserved to the U.S. government shall in no way be affected by this Agreement.

 

(c)                                  Ra acknowledges that Brigham and Women’s Hospital retains a continuing right to use any invention described and/or claimed in the Patent Rights for clinical, educational and research purposes.

 

2.4                               Other Materials and Know-How. horsier will identify to Ra chemicals and other materials, equipment and know-how that are not owned or controlled by the Brigham and Women’s Hospital useful for the practice of the Patent Rights and will provide reasonable consultation with respect thereto separate and apart from any role Forster has with Ra. including as a member of Ra’s Scientific Advisory Board pursuant to Section 3.2.

 

2.5                               No Additional Rights. Nothing in this Agreement shall be construed to confer any rights upon Ra by implication, estoppel, or otherwise as to patent rights of Forster other than the Patent Rights.

 

ARTICLE 3
 DILIGENCE OBLIGATIONS

 

3.1                               Due Diligence. Ra will use. or cause its Affiliates or Sublicensees to use. commercially reasonable efforts to research, develop and commercialize the Patent Rights or at least one Licensed Product, exerting such efforts and employing such resources as would normally be exerted or employed by a similarly situated company for a product of similar market potential, profit potential and strategic value at a similar stage of its product life, taking into account the competitiveness of the relevant marketplace, the patent, intellectual property and development positions of third parties, the applicable regulatory situation, the commercial viability of the product and other relevant development and commercialization factors based upon then-prevailing conditions.

 

3.2                               Scientific Advisory Board. Promptly following the Effective Date. Ra shall offer Forster a position on Ra’s Scientific Advisory Board under a mutually acceptable agreement, which shall provide compensation of $2,000 per in-person meeting and reimbursement of reasonable travel and accommodation expenses as approved by Ra in writing.

 

ARTICLE 4
 ROYALTIES AND PAYMENT TERMS

 

4.1                               License Issue Fee. Ra shall pay to Forster a non-refundable license issue fee of One Hundred Seventy-Three Thousand Five Hundred Forty-Seven U.S. dollars and Fifty cents (U.S. $173,547.50) in the manner prescribed in this Section 4.1. The option fee in the amount of Forty Thousand U.S. dollars (U.S. $40,000) and the Option Term extension fee of Thirty Thousand U.S. dollars (U.S. $30,000) paid by Ra to Forster (or to third parties designated by Forster) under the Option Agreement shall be credited against such One Hundred Seventy-Three Thousand Five Hundred Forty-Seven U.S. dollars and Fifty cents (U.S. $173,547.50) license issue fee, with the remaining One Hundred Three Thousand Five I kindred Forty-Seven U.S. dollars and Fifty cents (U.S. $103,547.50) due within ten (10) days after the Effective Date.

 

4.2                               Annual License Fee. For so long as Ra has an exclusive license under Patent Rights pursuant to Section 2.1 hereinbefore subject however to the rights retained by Forster. Brigham and Women’s Hospital, and the US Government pursuant to Section 2.3 hereinbefore, and beginning on the first anniversary of the Effective Date and continuing each anniversary thereafter until the first commercial sale of a Licensed Product. Ra shall pay to Forster an annual license fee of Fourteen Thousand Eight Hundred Seventy-Five U.S. dollars and Fifty Cents (U.S. $14,875.50) within thirty (30)

 

4

 

days after the applicable anniversary of the Effective Date. Such annual license fee will be fully creditable against royalty payments due and payable in any given year.

 

4.3                               Equity. Subject to approval by Ra’s Board of Directors. Ra shall grant to Forster an option (the “Forster Stock Option”) to purchase Fifty Nine Thousand Five Hundred Two (59,502) shares of Common Stock of Ra (the “Ra Stock”), at an exercise price equal to the fair market value of the Common Stock as of the date of grant, pursuant to Ra’s 2010 Stock Option and Grant Plan (the “Plan’’). The present fair market value is $0.01 per share. The Forster Stock Option will be subject to the terms and conditions applicable to options granted under the Plan, as described in the Plan and the applicable stock option grant agreement. The Ra Stock underlying the Forster Stock Option shall be subject to a vesting schedule with Fourteen Thousand Eight Hundred Seventy-Seven (14,877) shares vested upon grant, and the remainder shall vest during the Term on a straight-line quarterly basis over three (3) years. In the event this Agreement is terminated for any reason other than by Forster pursuant to Section 12.2, all vesting of the Ra Stock shall immediately cease and the Forster Stock Option shall terminate in accordance with the Plan and the applicable stock option grant agreement.

 

4.4                               Running Royalties.

 

(a)                                 For so long as Ra has an exclusive license under Patent Rights pursuant to Section 2.1 hereinbefore subject however to the rights retained by Forster. Brigham and Women’s Hospital, and the US Government pursuant to Section 2.3 hereinbefore, Ra shall pay lo Forster a running royalty equal to 0.25% of Net Sales of Licensed Products sold or transferred by Ra. its Affiliates and Sublicensees (in those countries where such sale or transfer then infringes any Valid Claims contained in the Patent Rights).

 

(b)                                 Running royalties shall be payable on an annual basis and shall be due to Forster within sixty (60) days of the end of each calendar year.

 

(c)                                  On sales of Licensed Products between Ra and its Affiliates and/or Sublicensees for resale, the royalty shall be paid on the resale.

 

(d)                                 To the extent that Ra or any of its Affiliates or Sublicenses obtains licenses to third party patent rights or other intellectual property in order to practice the Patent Rights or to develop or commercialize any Licensed Products. Ra may deduct from any royalty due to Forster hereunder the royalties due according to agreements between Ra (and its Affiliates and Sublicensees, as applicable) and a third party(ies) on such patents or intellectual property up to an amount equal to fifty percent (50%) of the running royalties owed in any calendar year hereunder, with any excess third party royalties carried over into next succeeding calendar year until exhausted. For clarity, Ra agrees that ii will not have the right lo so reduce any royalty payments due to Blacklow under Section 4.5(d).

 

(e)                                  If the manufacture, use or sale of any Licensed Product is covered by more than one of the Patent Rights, multiple royalties shall not be due.

 

(f)                                   The royally obligations of Ra shall continue on a country-by-country basis as to each Licensed Product commencing on the first commercial sale of the applicable Licensed Product and continuing until the expiration or termination of the last to expire of a Valid Claim within Patent Rights that covers such Licensed Product in the applicable country. Upon the termination of Ra’s royalty obligations with respect to a Licensed Product in a country, the license grants contained in Section 2.1 shall become fully paid-up and royalty-free for such Licensed Product in such country .

 

4.5                               Consideration Payable to Blacklow. As a matter of mutual convenience, Ra has agreed to pay Blacklow the following consideration owed by Forster lo Blacklow under the Blacklow Assignment as a result of entering into this Agreement as follows:

 

5

 

(a)                                 Ra shall pay to Blacklow a license issue fee of One Thousand Four Hundred Fifty Two U.S. dollars and Fifty cents (U.S. $1,452.50) within ten (10) days after the Effective Date.

 

(b)                                 Beginning on the first anniversary of the Effective Date and continuing each anniversary thereafter until the first commercial sale of a Licensed Product. Ra shall pay to Blacklow an annual license fee of One Hundred Twenty-Four U.S. dollars and Fifty Cents (U.S. $124.50) within thirty (30) days after the applicable anniversary of the Effective Date.

 

(c)                                  Subject to approval by Ra’s Board of Directors, Ra shall grant to Blacklow an option (the “Blacklow Stock Option”) to purchase Four Hundred Ninety Eight (498) shares of Ra Stock, at an exercise price equal to the fair market value of the Common Stock as of the date of grant pursuant to the Plan. The Blacklow Stock Option will be subject to the terms and conditions applicable to options granted under the Plan, as described in the Plan and the applicable stock option grant agreement. Forster acknowledges that Ra intends to obtain a third-party valuation to advise its Board of Directors on the fair market value of its Common Stock, which may delay the grant to Blacklow of the Blacklow Stock Option. The Ra Stock underlying the Blacklow Stock Option shall be subject to a vesting schedule with One Hundred Twenty Three (123) shares vested upon grant, and the remainder shall vest during the Term on a straight-line quarterly basis over three (3) years. In the event this Agreement is terminated for any reason other than by Forster pursuant to Section 12.2, all vesting of the Ra Stock shall immediately cease and the Blacklow Stock Option shall terminate in accordance with the Plan and the applicable stock option grant agreement

 

(d)                                 Ra shall pay to Blacklow a running royalty equal to 0.25% of Net Sales of Licensed Products sold or transfer by Ra. Affiliates and Sublicensees in those countries where such sale or transfer then infringes any Valid Claims contained in the Patent Rights. Running royalties shall be payable on an annual basis and shall be due to Blacklow within sixty (60) days of the end of each calendar year.

 

(e)                                  Forster hereby represents and warrants that the amounts payable to Blacklow in this Section 4.5 shall satisfy in full all consideration owed lo Blacklow under the Blacklow Assignment and all other contractual obligations with Blacklow relating to the Patent Rights. Forster shall provide complete and accurate payment and other instructions to Ra to enable Ra to comply with its payments obligations to Blacklow.

 

4.6                               Buy-Out Right. At any time during the Term of this Agreement, Ra shall have the right and option, in its sole discretion, to terminate all of Ra’s payment obligations owed to Forster, bin not to Blacklow. under this Agreement by paying to Forster an amount equal to Seven Hundred Fifty Thousand U.S. dollars (U.S. $750,000), less a credit for (a) all royalties paid by Ra under this Agreement through the date that Ra exercises its buy-out option; and (b) all annual license fees paid by Ra under this Agreement through the date that Ra exercises its buy-out option that have not previously been credited against royalties payable by Ra.

 

4.7                               Method of Payment. All payments under this Agreement to “Anthony Forster” and “Stephen C. Blacklow” and should be sent to the addresses identified in Section 14.1.

 

4.8                               Payments in U.S. Dollars. All payments due under this Agreement shall be payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working day of the calendar quarter of the applicable calendar year. Such payments shall be without deduction of exchange, collection, or other charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as permitted in the definition of Net Sales.

 

4.9                               Late Payments. Late payments shall be subject to an interest charge of one percent (1%) per month.

 

6

 

ARTICLE 5
 REPORTS AND RECORDS

 

5.1                               Reports.

 

(a)                                 Ra shall report to Forster the date of first commercial sale of a Licensed Product within sixty (60) days of occurrence in each country.

 

(b)                                 After the first commercial sale of a Licensed Product. Ra shall deliver reports to Forster within sixty (60) days of the end of each calendar year, setting forth at least the information concerning the immediately preceding calendar year, as further described in Section 5.2.

 

5.2                               Content of Reports and Payments. Each report delivered by Ra to Forster shall contain at least the following information for the immediately preceding calendar year:

 

(a)                                 the number of Licensed Products sold by Ra, its Affiliates and Sublicensees to independent third parties in each country;

 

(b)                                 the gross price charged by Ra, its Affiliates and Sublicensees for each Licensed Product sold by Ra, its Affiliates and Sublicensees in each country;

 

(c)                                  calculation of Net Sales for the applicable calendar year in each country, including, without limitation, a listing of applicable deductions; and

 

(d)                                 total royalty payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion.

 

If no amounts are due to Forster for any calendar year, the report shall so state.

 

5.3                               Records. Ra shall maintain, and shall cause its Affiliates and Sublicensees to maintain, complete and accurate records relating to amounts payable to Forster in relation to this Agreement. The relevant entity shall retain such records for at least three (3) years following the end of the calendar year to which they pertain. They shall be available during normal business hours for inspection, at the expense of Forster, by a certified, independent public accountant selected by Forster and reasonably acceptable to Ra for the sole purpose of verifying any reports and payments made or compliance in other respects under this Agreement. In the event that any audit performed under this Section 5.3 reveals an underpayment in excess often percent (10%), Ra shall bear the full out-of-pocket cost of such audit and shall remit any amounts due to Forster within thirty (30) days of receiving notice thereof from Forster.

 

5.4                               Confidentiality. The reports and records provided by Ra hereunder shall be regarded as Ra’s confidential information and Forster hereby covenants that it shall not use or disclose any information included in such reports for any purpose other than determining whether Ra. its Affiliates and Sublicensees have complied with their obligations under this Agreement. Forster further agrees that, until such time as such information is no longer confidential through no fault of Forster. it shall maintain such reports and any information included therein in strict confidence, except as required by law, including Public Law 96-517 and 98-620, and treat such information in a manner at least as restrictive as its manner of treating its own confidential information of similar nature and in any event not less than with a reasonable degree of care.

 

ARTICLE 6
 PATENT PROSECUTION

 

6.1                               Responsibility for Patent Rights. Forster hereby appoints Ra as its agent to prepare, file, prosecute, maintain and defend in all agency proceedings (e.g.. reissues, reexaminations, oppositions and interferences) all of the Patent Rights during the Term. Ra shall copy Forster on all patent prosecution documents and give Forster reasonable opportunities to advise Ra on such filing, prosecution and

 

7

 

maintenance. All costs for obtaining, prosecuting, maintaining, and defending the Patent Rights of this license shall be the responsibility of Ra. and any reasonable out-of-pocket expenses incurred by Forster after the Effective Date will be reimbursed to him b> Ra. In the event Ra desires to abandon any patent or patent application within the Patent Rights. Ra shall provide Forster with reasonable prior written notice of such intended abandonment or decline of responsibility. If Forster elects to continue such patent or patent application, the Parties shall consult and Ra may elect to retain responsibility therefor. Otherwise, the right to prepare, file, prosecute, maintain and defend the relevant Patent Rights, at Forster’s expense, shall revert to Forster. In such event, such Forster paid-fur rights shall be removed from the definition of Patent Rights under this Agreement and the licenses granted to Ra and its Affiliates as to such rights shall terminate. Each Party shall provide to the other prompt notice as to all matters which come to its attention and which may affect the preparation, filing, prosecution or maintenance of any such patent applications or patents.

 

6.2                               Payment of Expenses.

 

(a)                                 Within ten (10) days after the Effective Date. Ra shall, as directed by Forster, pay lo Brigham and Women’s Hospital, one thousand nine hundred and ninety three dollars and twenty cents ($1,993.20) for Brigham’s unreimbursed patent costs related to the Patent Rights, as required under the Letter to Forster from Brigham and Women’s Hospital dated September 8. 2000. a copy of which has been provided to Ra. Such payment shall be made by check made payable to The Brigham and Women’s Hospital, Inc. and addressed as set forth below:

 

Brigham and Women’s Hospital 
 BOA-Lockbox Services 
 PCSR Lockbox #415007 
 MA 5-527-02-07 
 2 Morrissey Blvd 
 Dorchester. MA 02125

 

(b)                                 Payment of all reasonable out-of-pocket lees and costs incurred by Forster in obtaining, prosecuting, maintaining and defending the Patent Rights between the effective date of the Option Agreement and the Effective Date shall be the responsibility of Ra.

 

6.3                               Patent Extensions and Orange Book Listings. If elections with respect to obtaining patent term extensions (including, without limitation, any available pediatric extensions) or supplemental protection certificates or their equivalents in any country with respect to Patent Rights are available, Ra shall have the sole and exclusive right to make any such elections based on Licensed Products. With respect to data exclusivity periods (such as those periods listed in the FDA’s Orange Book (including, without limitation, any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or orphan exclusivity periods, and all equivalents in any country I. Ra shall have the sole and exclusive right to seek and maintain all such data exclusivity periods available for the Licensed Products. With respect to all of the rights and activities identified in this Section 6.3, Forster hereby appoints Ra as its agent for such purposes with the authority to act on Forster’s behalf with respect to the Patent Rights in a manner consistent with this Agreement.

 

ARTICLE 7
 INFRINGEMENT

 

7.1                               Infringement. Section 8.1(c) addresses infringement of the Licensed Patents.

 

7.2                               Declaratory Judgment Actions. If a declaratory judgment or other similar action is brought naming Forster or Ra or any of its Affiliates or Sublicensees as a defendant and alleging invalidity, unenforceability, non-infringement or any issues relating to inventorship or ownership of any

 

8

 

Patent Rights, Ra or Forster, as the case may be, shall promptly notify the other Party in writing and Ra shall have the sole and exclusive right, but shall not be obligated, to have sole control of such action at its own expense.

 

7.3                               Patent Certifications. Forster shall notify and provide Ra with copies of any allegations of alleged patent invalidity, unenforceability or non-infringement of a Patent Right pursuant to a Paragraph IV Patent Certification by a third party filing an Abbreviated New Drug Application, an application under §505(b)(2) or any other similar patent certification by a third party, and any foreign equivalent thereof. Such notification and copies shall be provided to Ra within five (5) business days after Forster receives such certification.

 

7.4                               Settlement. No settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the consent of Forster if such settlement, judgment or disposition would place additional obligations on Forster or grant additional rights to Ra other than those already contained in this Agreement, which consent shall not be unreasonably withheld.

 

ARTICLE 8
 INDEMNIFICATION AND INSURANCE

 

8.1                               Indemnification.

 

(a)                                 Ra hereby agrees to indemnify, defend and hold harmless Forster from and against all damages, liabilities, losses and other expenses, including, without limitation, reasonable attorney’s fees, and expenses of litigation, regarding any claims, suits or proceedings brought by a third party (collectively “Claim”), that arise out of or relate to (a) any product, process, or service that is made, used, sold, imported, or performed pursuant to any right or license granted under this Agreement, (b) Ra’s failure to comply with any applicable laws, rules or regulations in connection with this Agreement, (c) the negligent or willful acts or omissions of Ra, and (d) any theory of product liability (including but not limited to actions in the form of tort, warranty or strict liability concerning any product, process or service made, used or sold pursuant to any right or license granted under this Agreement, except that Ra’s liability for damages under its indemnity shall be reduced or apportioned to the extent any claim is proximately caused by Forster’s gross negligence or willful misconduct.

 

(b)                                 Ra hereby agrees to indemnify, defend and hold harmless Brigham and Women’s Hospital and its affiliates and their respective trustees, directors, officers, medical and professional staff, employees and agents and their respective successors, heirs and assigns from and against all damages, liabilities, losses and other expenses, including, without limitation, reasonable attorney’s fees, regarding any Claims that arise out of or relate to (a) any product, process, or service that is made, used, sold, imported, or performed pursuant to any right or license granted under this Agreement, (b) Ra’s failure to comply with any applicable laws, rules or regulations in connection with this Agreement, and (c) the negligent or willful acts or omissions of Ra, except that Ra’s liability for damages under its indemnity shall be reduced or apportioned to the extent any claim is proximately caused by Brigham and Women’s Hospital’s gross negligence or willful misconduct.

 

(c)                                  If any third party shall, in the reasonable opinion of either Party, infringe any of the Licensed Patents, such Party shall promptly notify the other Party. Ra shall then have the sole and exclusive right to initiate a legal proceeding for infringement against the third party, in its own name and/or in the name of the Forster if necessary, together with the right to enforce and collect any judgment thereon. If Ra elects to exercise such right, (i) Forster shall, al Ra’s request, take all appropriate or necessary actions to assist in the prosecution of such proceeding (including consenting lo being joined in such proceeding), (ii) Forster shall bear the internal legal and other costs incurred by Forster in taking such actions, and shall be reimbursed by Ra for the reasonable external out-of

 

9

 

pocket expenses paid to attorneys and consultants retained in connections with taking such requested actions and (iii) Ra shall hear its own internal and external legal and other costs and expenses, together with all other costs and expenses associated with the proceeding (including without limitation court costs). Any monetary recovery in connection with such infringement action shall he applied to reimburse Ra for its out-of-pocket expenses (including reasonable attorneys and consultants’ fees) in prosecuting such proceeding and the expenses of Forster reimbursed by Ra hereunder. Any balance shall be retained by Ra. During the pendency of any such proceeding, royalties payable under this Agreement shall remain payable.

 

(d)                                 Forster hereby agrees to indemnify, defend and hold harmless Ra and any Affiliates and their respective directors, officers, employees, agents, successors, assigns and other representatives from and against all damages, liabilities, losses and other expenses, including, without limitation, reasonable attorney’s fees, regarding any Claims that arise out of or relate to (a) any claim that Forster has not fulfilled his obligations to Brigham and Women’s Hospital or the National Institutes of Health, (b) any claim that Forster has failed to comply with his obligations to Blacklow, except to the extent such failure was caused by Ra’s failure to comply with its obligations under this Agreement, (c) Forster’s failure to comply with any applicable laws, rules or regulations in connection with this Agreement, and (d) the negligent or willful acts or omissions of Forster. except that Forster’s liability for damages under its indemnity shall be reduced or apportioned lo the extent any claim is proximately caused by the Ra’s gross negligence or willful misconduct.

 

(e)                                  the indemnifying Party shall not enter into any settlement of such Claims that do not unconditionally release the indemnified Party from all liability or that imposes any obligation on the indemnified Party without the indemnified Party’s prior written consent. Notwithstanding the above, the indemnified Party, at his or its expense, shall have the right to retain separate independent counsel to assist in defending any such Claims. In the event the indemnifying Party fails to promptly indemnify and defend such Claims or pay the indemnified Party’s expenses as provided above, the indemnified Party shall have (he right to defend himself or itself, and in that case, the indemnifying Party shall reimburse the indemnified Party for all of reasonable attorney’s fees, costs and damages incurred in settling or defending such Claims within thirty (30) days of each of the indemnified Party’s written requests. This indemnity shall be a direct payment obligation and not merely a reimbursement obligation of the indemnifying Party 10 the indemnified Party.

 

8.2                               Insurance. Ra shall obtain and carry in full force and effect commercial general liability insurance, in amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate and naming the indemnified parties in Section 8.1 above as additional insureds. Upon initiation of a human clinical trial of any Licensed Product. Ra shall carry Product Liability in an amount no less than $2,000,000 per incident and $2.000,000 annual aggregate and naming the indemnified parties in Section 8.1 above as additional insureds. If Ra elects to self insure all or parts of the limits described above (including deductibles or retentions which are in excess of $250,000 annual aggregate) such self-insurance program must be acceptable to the Brigham and Women’s Hospital and the Risk Management Foundation. The minimum amounts of insurance coverage required under this Section 8.2 shall not be construed to create a limit of Ra’s liability with respect to its indemnification under Section 8.1 above. Ra shall continue to maintain such insurance for five (5 ) years after expiration or termination of this Agreement.

 

ARTICLE 9
 REPRESENTATIONS OR WARRANTIES

 

9.1                               Representations and Warranties.

 

(a)                                 Each Party represents, warrants and covenants lo the other that (i) it has the corporate or other power and authority and the legal right to enter into this Agreement and perform its obligations hereunder: (ii) if has taken all necessary corporate or other action on its part required to

 

10

 

authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and (hi) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance with its terms.

 

(b)           Forster represents and warrants that: (i) Forster solely and exclusively owns the patents and applications included within the Patent Rights; (ii) Forster has the power and authority to grant the licenses provided for herein to Ra; (iii) Forster has not entered, and shall not enter, into any agreement with any third Party that is in conflict with the rights granted to Ra herein, and Forster has not taken and will not take any action that would in any way prevent Forster from granting the rights granted to Ra under this Agreement, or that would otherwise materially conflict with or adversely affect the rights granted to Ra under this Agreement; (iv) Forster’s performance and execution of this Agreement does not and will not result in a breach of any other contract lo which Forster is a party or to which the Patent Rights relate: (v) to Forster’s knowledge, there is no infringement of the Patent Rights by any third party; (vi) pursuant to Section 4.5, Forster or Ra has paid, and/or will pay. all consideration payable to Blacklow under the Blacklow Assignment and any other obligations relating to the Patent Rights; and (vii) there are no patent rights (either issued, pending, or available for filing) that claim priority to any of the patents or patent applications listed on Exhibit A (or any parent patent application thereof), other than the Patent Rights. Forster does not warrant the validity of the Patent Rights licensed hereunder and makes no representations whatever with respect to the scope of the licensed Patent Rights.

 

9.2          Disclaimer of Warranties. Except as otherwise be expressly set forth in this Agreement neither Party makes any other representations or extends any warranties of any kind, either express or implied, including, but not limited to, any express or implied warranties of merchantability. Illness for a particular purpose or non-infringement.

 

9.3          Limitation of Liability. Except for Ra’s indemnity obligations under section 8.1, in no event shall either Party be liable for any indirect or incidental damages such as damages for loss of profits or expected savings or other economic losses arising out of or in connection with this Agreement or its subject matter. Forster expressly disclaims any and all implied or express warranties and makes no express or implied warranties of merchantability. Illness for any particular purpose of the patent rights, information supplied by Forster. licensed processes or licensed products contemplated by this Agreement.

 

ARTICLE 10
 ASSIGNMENT

 

This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided, however, that (a) Ra may, without such consent, but with notice to Forster. assign this Agreement, in whole or in part, (i) in connection with the transfer or sale of all or substantially all of its assets or the line of business to which this Agreement relates, (ii) to a successor entity or acquirer in the event of a merger, consolidation, reorganization or change of control, or (iii) to any Affiliate; and (b) upon the death or incapacity of Forster, the rights of Forster will be. upon written notice (by a survivor or legal proxy of Forster. or by Forster’s estate) to Ra, assigned to Forster’s wife, or failing that, jointly to Forster’s children, or failing that, jointly to Forster’s parents and sister, or failing that as directed by Forster’s estate. This assignment may be changed by Forster with written notice to Ra. Any purported assignee will assume the rights and obligations of its assignor under this Agreement.

 

11

 

ARTICLE 11
 USE OF NAMES; MARKING

 

11.1        Non-Use of name by Ra. Ra and its Affiliates and Sublicensees shall not use the name of “Forster” or “Brigham and Women’s Hospital” or any trustee, director, officer, staff member, employee, student or agent of Brigham and Women’s Hospital or any variation, adaptation, or abbreviation thereof, or any terms of this Agreement in any publicity, advertising, promotional or sales material or other public announcement or disclosure or in any document employed to obtain funds or financing without the prior written consent of Forster or Brigham and Women’s Hospital, as applicable. In the case of the Brigham and Women’s Hospital, such consent shall be obtained from the Hospital’s VP of Public Affairs. The foregoing notwithstanding, without the consent of Forster and Brigham and Women’s Hospital, (i) Ra may state as a matter of fact that it is licensed by Forster under the Patent Rights (without any reference to Blacklow, Brigham and Women’s Hospital or any trustee, director, officer, staff member, employee, student or agent of Brigham and Women’s Hospital or any variation, adaptation, or abbreviation thereof), and (ii) Ra may identify Blacklow and Brigham and Women’s Hospital and their relationship to Ra solely to comply with disclosure requirements of all applicable laws relating to its business, including, without limitation. United States and state securities laws.

 

11.2        Marking of Licensed Products. To the extent commercially feasible and consistent with prevailing business practices, Ra shall mark, and shall cause its Affiliates and Sublicensees to mark, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

 

ARTICLE 12
 TERMINATION

 

12.1        Voluntary Termination by Ra. Ra shall have the right to terminate this Agreement for any reason, upon at least thirty (30) days prior written notice to Forster, such notice to state the date at least thirty (30) days in the future upon which termination is to be effective.

 

12.2        Termination for Default.

 

(a)           In the event Ra fails to pay any undisputed amounts due and payable to Forster hereunder, and fails to make such payments with interest within thirty (30) days after receiving written notice of such failure, Forster may terminate this Agreement immediately upon written notice to Ra subject to completion of the dispute resolution process set forth in Article 13 and subsequent cure.

 

(b)           In the event Ra commits a material breach of its obligations under this Agreement, except for breach as described in Section 12.2(a). and fails to cure that breach within ninety (90) days after receiving written notice thereof, Forster may terminate this Agreement immediately upon written notice to Ra. subject to completion of the dispute resolution process set forth in Article 13 and subsequent cure.

 

(c)           In the event that Ra shall make an assignment for the benefit of creditors, or shall have a petition in bankruptcy filed for or against it (and such petition is not dismissed within sixty (60) days of filing), Forster shall have the right to terminate this entire Agreement immediately upon giving Ra written notice of such termination.

 

12.3        Effect of Expiration or Termination.

 

(a)           The following provisions shall survive the expiration or termination of this Agreement: Article I, Article 8, Article 9, Article 10. Article 13 and Article 14, and Sections 2.2 (but only with respect to the effect of termination on Sublicensees), 4.4 (lo the extent that any royalties

 

12

 

were due while this Agreement was in effect). 5.2 (but only with respect to obligation to provide final report and payment), 5,3, 5.4, 11.1 and 12.3.

 

(b)           Upon the early termination of this Agreement, Ra and its Affiliates and Sublicensees may complete and sell any work-in-progress and inventory of Licensed Products that exist as of the effective date of termination, provided that (i) Ra pays Forster and Blacklow the applicable running royally or other amounts due on such sales of Licensed Products in accordance with the terms and conditions of this Agreement, (ii) Ra and its Affiliates and Sublicensees shall complete and sell all work-in-progress and inventory of Licensed Products within six (6) months after the effective date of termination and (iii) Ra shall continue to be subject to the obligations specified under Article 8.

 

(c)           Expiration or termination of this Agreement for any reason shall not relieve either Party of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration.

 

ARTICLE 13
 DISPUTE RESOLUTION

 

13.1        Mandatory Procedures. The Parties agree that any dispute arising out of or relating to this Agreement or the breach thereof, the Parties shall try to settle said dispute amicably between themselves, any such disputes which the Parties are unable to resolve shall be resolved solely by means of the procedures set forth in this Article 13. and that such procedures constitute legally binding obligations that are an essential provision of this Agreement. If either Party fails to observe the procedures of this Article 13. as may be modified by their written agreement, the other Party may bring an action for specific performance of these procedures in any court of competent jurisdiction.

 

13.2        Equitable Remedies. Although the procedures specified in this Article 13 are the sole and exclusive procedures for the resolution of disputes arising out of or relating to this Agreement, either Party may seek a preliminary injunction or other provisional equitable relief if, in its reasonable judgment, such action is necessary to avoid irreparable harm lo itself or to preserve its rights under this Agreement.

 

13.3        Dispute Resolution Procedures. Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by binding confidential arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”), and the procedures set forth below. In the event of any inconsistency between the Rules of AAA and the procedures set forth below, the procedures set forth below shall control. Judgment upon the award rendered by the arbitrators may be enforced in any court having jurisdiction thereof. The award through arbitration shall be final and binding.

 

(a)           The location of the arbitration shall be in Boston. Massachusetts. Forster and Ra hereby irrevocably submit to the exclusive jurisdiction and venue of the AAA arbitration panel selected by the Parties and located in Boston, Massachusetts for any dispute regarding this Agreement, and to the exclusive jurisdiction and venue of the federal and state courts located in Boston. Massachusetts for any action or proceeding to enforce an arbitration award or as otherwise provided in Section 13.3(e), and waive any right to contest or otherwise object to such jurisdiction or venue.

 

(b)           The arbitration shall be conducted by a panel of three neutral arbitrators who are independent and disinterested with respect to the Parties, this Agreement, and the outcome of the arbitration. Each Party shall appoint one neutral arbitrator, and these two arbitrators so selected by the Parties shall then select the third arbitrator, and all arbitrators must have at least ten (10) years experience in mediating or arbitrating cases regarding the same or substantially similar subject matter

 

13

 

as the dispute between Forster and Ra. (Tone Party has given written notice to the other Party as to the identity of” the arbitrator appointed by the Party, and the Party thereafter makes a written demand on the other Party to appoint its designated arbitrator within the next ten days, and the other Party fails to appoint its designated arbitrator within ten days after receiving said written demand, then the arbitrator who has already been designated shall appoint the other two arbitrators.

 

(c)           The arbitrators shall decide any disputes and shall control the process concerning these pre-hearing discovery matters. Pursuant to the Rules of AAA, the Parties may subpoena witnesses and documents for presentation at the hearing.

 

(d)           Prompt resolution of any dispute is important to both Parties: and the Parties agree that the arbitration of any dispute shall be conducted expeditiously. The arbitrators are instructed and directed to assume case management initiative and control over the arbitration process (including, without limitation, scheduling of events, pre-hearing discovery and activities, and the conduct of the hearing), in order to complete the arbitration as expeditiously as is reasonably practical for obtaining a just resolution of the dispute.

 

(e)           The arbitrators may grant any legal or equitable remedy or relief that the arbitrators deem just and equitable, to the same extent that remedies or relief could be granted by a state or federal court, provided however, that no punitive damages may be awarded. No court action shall be maintained seeking punitive damages. The decision of any two of the three arbitrators appointed shall be binding upon the Parties. Notwithstanding anything to the contrary in this Agreement, prior lo or while an arbitration proceeding is pending, either Party has the right to seek and obtain injunctive and other equitable relief from a court of competent jurisdiction to enforce that Party’s rights hereunder.

 

(f)            The expenses of the arbitration, including, without limitation, the arbitrators* fees, expert witness fees, and attorney’s fees, may be awarded to the prevailing Party, in the discretion of the arbitrators, or may be apportioned between the Parties in any manner deemed appropriate by the arbitrators. Unless and until the arbitrators decide that one Party is to pay for all (or a share) of such expenses, both Parties shall share equally in the payment of the arbitrators’ fees as and when billed by the arbitrators,

 

(g)           Notwithstanding the foregoing, any disputes arising hereunder with respect to the inventorship, ownership, validity, enforceability or other aspect of intellectual property rights shall be resolved by a court of competent jurisdiction and not by arbitration.

 

(h)           Except as set forth below and as necessary to obtain or enforce a judgment upon any arbitration award, the Parties shall keep confidential the fact of the arbitration, the dispute being arbitrated, and the decision of the arbitrators. Notwithstanding the foregoing, the Panics may disclose information about the arbitration to persons who have a need to know, such as directors, trustees, management employees, witnesses, experts, investors, attorneys, lenders, insurers, actual or potential collaborators or corporate partners of Ra, actual or potential acquirers of Ra, and others who may be directly affected provided that such persons are hound to keep such information confidential. Additionally, if a Party has stock which is publicly traded, the Party may make such disclosures as are required by applicable securities laws, but shall use commercially reasonably efforts to seek confidential treatment for such disclosure.

 

13.4        Performance to Continue, Each Party shall continue to perform its undisputed obligations under this Agreement pending final resolution of any dispute arising out of or relating to this Agreement: provided, however, that a Party may suspend performance of its undisputed obligations during any period in which the other Party fails or refuses to perform its undisputed obligations.

 

14

 

13.5        Statute of Limitations. The Parties agree that all applicable statutes of limitation and lime-based defenses (such as estoppel and laches) shall be tolled while the procedures set forth in Section 13.5 are pending. The Panics shall cooperate in taking any actions necessary to achieve this result.

 

ARTICLE 14
 MISCELLANEOUS

 

14.1        Notice. Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by hand, recognized national overnight courier, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers of the Parties:

 

	
If   to Forster:
    	
 
    
	
 
    	
 
    
	
 
    	
Anthony   C. Forster. M.D., Ph.D.
    
	
 
    	
357   Childe Harold’s Circle
    
	
 
    	
Brentwood,   TN 37027
    
	
 
    	
 
    
	
If   to Ra:
    	
 
    
	
 
    	
 
    
	
 
    	
Ra   Pharmaceuticals. Inc.
    
	
 
    	
c/o   Morgenthaler Ventures
    
	
 
    	
222   Berkeley Street, 20th Floor
    
	
 
    	
Boston,   MA 02116
    
	
 
    	
Attention:   Douglas A. Treco, Ph.D.
    
	
 
    	
 
    
	
With   a copy to;
    	
 
    
	
 
    	
 
    
	
 
    	
Goodwin   Procter LLP
    
	
 
    	
53   State Street
    
	
 
    	
Boston,   MA 02109-2802
    
	
 
    	
Attention:   Kingsley L. Taft, Esq.
    
	
 
    	
 
    
	
If   to Blacklow;
    	
 
    
	
 
    	
 
    
	
 
    	
Dr. Stephen   C. Blacklow
    
	
 
    	
16   Ash Street
    
	
 
    	
Cambridge,   MA 02138
    
	
 
    	
 
    
	
If   to Brigham and Women’s Hospital:
    
	
 
    	
 
    
	
 
    	
Executive   Director. Research, Ventures and Licensing
    
	
 
    	
Brigham   and Women’s Hospital
    
	
 
    	
101   Huntington Avenue, 4th Floor
    
	
 
    	
Boston,   MA 02199-8001
    
	
 
    	
Fax   No. (617) 954-9361
    
	
 
    	
Agreement   No. A207428
    
	
 
    	
 
    

All notices under this Agreement shall he deemed effective upon receipt. A Party may change its contact information immediately upon written notice to the other Party in the manner provided in this Section 14.1. Ra M ill provide Forster with an account number for making charges to a suitable express mail service should any expedited mailings be necessary, or reimburse him for any out-of-pocket expenses incurred.

 

15

 

14.2        Governing Law. This Agreement and all disputes arising out of or related to this Agreement, or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Massachusetts, without regard to conflict of laws principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted.

 

14.3        Force Majeure. Neither Party shall be responsible for delays resulting from causes beyond the reasonable control of such Party, including, without limitation fire, explosion, flood, war. strike, or riot, provided that the nonperforming Party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed.

 

14.4        Amendment and Waiver, This Agreement may be amended, supplemented, or otherwise modified only by means of a written instrument signed by both Parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

 

14.5        Severability. In the event that any provision of this Agreement shall be held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement, and the Parties shall negotiate in good faith to modify the Agreement to preserve (to the extent possible) their original intent. If the Parties fail to reach a modified agreement within thirty (30) days after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance with the procedures set forth in Article 13, While the dispute is pending resolution, this Agreement shall be construed as if such provision were deleted by agreement of the Parties.

 

14.6        Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and assigns.

 

14.7        Third Party Beneficiaries. Except with respect to an indemnified Parties’ rights under Section 8.1. the provisions set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and assigns, and they shall not be construed as conferring any rights on any other persons.

 

14.8        Headings. All headings are for convenience only and shall not affect the meaning of any provision of this Agreement.

 

14.9        Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to its subject matter and supersedes all prior agreements or understandings between the Parties relating to its subject matter, including, without limitation, the Option Agreement.

 

14.10      Counterparts; Signatures. This Agreement may be executed in any number of counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. Facsimile or PDF signatures shall be treated as original signatures.

 

[remainder of this page intentionally left blank]

 

16

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

 

	
Anthony C. Forster.   M.D., Ph.D.
    	
RA   PHARMACEUTICALS, INC.
    
	
 
    	
 
    
	
By:
    	
/s/ Anthony Forster
    	
By: 
    	
/s/ Douglas A. Treco
    
	
Name:
    	
Anthony C. Forster
    	
Name:
    	
Douglas A. Treco
    
	
 
    	
 
    	
Title: 
    	
President and CEO
    

 

 

 

 

	
Approved by The   Brigham and Women’s Hospital. Inc.
    	
 
    
	
 
    	
 
    
	
THE BRIGHAM AND WOMEN’S   HOSPITAL. INC.
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Vandana Yajnik
    	
 
    
	
Name:
    	
Vandana Yajnik
    	
 
    
	
Title:
    	
Director,   Research & Licensing,
    	
 
    
	
 
    	
Research   Ventures & Licensing
    	
 
    
	
Date:
    	
11/30/10
    	
 
    

 

 

EXHIBIT A

 

PATENT RIGHTS

 

Issued Patents:

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS United States of America Issued (US 6,977,150: Corresponding Appl. No. 10/057,783)

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS Australia Issued (Patent No. 2002255488)

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS Switzerland Issued (Patent No. 1356036; Corresponding Appl. No. 2724888.9)

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS Germany Issued (Patent No. 60226411.1-08; Corresponding Appl. No. 2724888.9)

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS European Patent Office Issued (EP 1 356 036 B1; Corresponding Appl. No. 2724888.9)

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS France Issued (Patent No. 1356036; Corresponding Appl. No. 2724888.9)

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS United Kingdom Issued (Patent No. 1356036; Corresponding Appl. No. 2724888.9)

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS Ireland Issued (Patent No. 1356036; Corresponding Appl. No. 2724888.9)

 

Pending Applications:

 

PROCESS AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS Canada Pending Appl. No. 2,435,812

 

PROCESS AND COMPOSITIONS FOR PEPTIDE. PROTEIN AND PEPTIDOMIMETIC SYNTHESIS Japan Pending Appl. No. 2002-559580Exhibit 10.13

 

CONFIDENTIAL

 

	
Gryphon   Therapeutics, Inc.
    	
Phylos, Inc.
    
	
600   Gateway Blvd.
    	
128   Spring St.
    
	
So.   San Francisco, CA 94080
    	
Lexington,   MA 02421
    
	
(“Gryphon”)
    	
(“Phylos”)
    

 

Research and Development Collaboration and License agreement

 

1                                                                                         Scope and Field.

 

1.1                               Set forth below is the agreement of Gryphon and Phylos, each sometimes referred to herein as a “Party” or collectively as the “Parties”, which hereby acknowledge that they have received adequate and sufficient consideration for entering into their respective and mutual agreements below.

 

1.2                               Gryphon wishes to apply Phylos’ PROfusionTM Technology in developing high affinity peptides.

 

1.3                               The Parties wish to establish a collaboration which will allow Gryphon to evaluate the PROfusion Technology in conjunction with its Cosmix Technology.

 

1.4                               Phylos wishes to grant Gryphon a nonexclusive license for the use of PROfusion Technology.

 

2                                                                                         Definitions.

 

2.1                               “Affiliate” means any corporation or non-corporate business entity which controls, is controlled by, or is under common control with a party to this Agreement. A corporation or non-corporate business entity shall be regarded as in control of another corporation if it owns or directly or indirectly controls at least fifty percent (50%) of the voting stock of the other corporation, or (a) in the absence of the ownership of at least fifty percent (50%) of the voting stock of a corporation, or (b) in the case of a non-corporate business entity, if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by contract or otherwise.

 

2.2                               “Cosmix Technology” means (a) all present and future patents, patent applications, reissued patents, re-examined patents, divisions, renewals, continuations and continuations-in-part, substitutions, extensions and foreign counterparts thereof owned, controlled by or licensed to Gryphon that relate to Cosmix-plexing® technology, as described in Exhibit A attached hereto and (b) all present and future techniques, inventions, discoveries, practices, methods, know-how, technical data and information (other than described in clause (a) of this Section 2.1) that are necessary or useful to practice the Cosmix-plexing® technology, that are not generally known and that are within the Control of Cosmix or its affiliates, “Control” meaning the right and ability to grant sublicenses.

 

2.3                               “Effective Date” means the date of execution of this Agreement by the last of the three signatories hereto.

 

2.4                               “D-Target” means a protein composed of D amino acids.

 

2.5                               “Gryphon Patent Rights” means those patents, patent applications, reissued patents, reexamined patents, divisions, renewals, continuations and continuations-in-part, substitutions, extensions and foreign counterparts thereof, relating to Gryphon’s D-screening technology set forth on Exhibit B hereto, and arising after the Effective Date but before completion of performance by Phylos under this Agreement or such earlier expiration or termination of this Agreement and agreed by the parties to be added to Exhibit B, but in all instances excluding Cosmix Technology).

 

1

 

2.6                               “Gryphon Know-How” means techniques, inventions and/or discoveries, practices, methods, knowledge, know-how, skill, technical data and information, and materials that are necessary or useful to the practice of Gryphon Patent Rights, that are not generally known and that are within the Control of Gryphon or its Affiliates as of the Effective Date or come into the Control of Gryphon or its Affiliates before completion of performance by Phylos under this Agreement or such earlier expiration or termination of this Agreement, but in all instances excluding know how related to Cosmix Technology and Gryphon Patent Rights.

 

2.7                               “Gryphon Technology” means the Gryphon Know-How and the Gryphon Patent Rights, collectively.

 

2.8                               “Gryphon” means Gryphon Therapeutics, Inc, a California corporation and its Affiliates

 

2.9                               “Major Market” means any of: the United States, Japan, Germany, France, the United Kingdom, Italy or Spain.

 

2.10                        “Owner” means the Party having rights to the Product.

 

2.11                        “PROfusionTM Technology” means compositions of matter (including, but not limited to reagents) and methods, whether or not patented or patentable, and know-how for in vitro protein evolution wherein peptide-encoding messenger RNA (“mRNA”) molecules are generated with a modification linking a peptide acceptor such as a puromycin molecule to the 3’ terminus of the mRNA molecule so that in vitro translation results in a peptide or protein covalently linked to its encoding nucleic acid via the 3’ terminus of the mRNA and the carboxyl terminus of the peptide or protein via a peptide acceptor such as a puromycin molecule and wherein peptides or proteins having a desired binding affinity are selected from libraries of these RNA-protein fusion molecules. The PROfusionTM Technology, including a description of peptide acceptors such as a puromycin molecule, includes, without limitation, the following family of patents: US 6,261,804; 6,258,558; 6,214,553; 6,281,344; and 6,207,446, and others listed on Exhibit E, and all reissues, reexaminations, renewals, divisionals, continuations, continuations-in-part and foreign counterparts of any of the foregoing.

 

2.12                        “Product” means any peptides or their derivatives identified during PROfusion Technology screening pursuant to this Agreement.

 

3                                                                                         Licenses and Intellectual Property.

 

3.1                               Gryphon hereby grants and will grant to Phylos and its Affiliates, a nonexclusive license under Gryphon Patent Rights solely for the purpose of conducting research and development activities in the performance of it obligations under this Agreement until the earlier of (i) completion of such activities hereunder or (ii) the earlier of expiration or termination of this Agreement.

 

3.2                               Phylos hereby grants and will grant to Gryphon and its Affiliates a worldwide, nonexclusive license under PROfusion Technology including future improvements and enhancements thereto, specifically for use with Peptide Libraries (as defined in Appendix C) to screen, make, have made, improve, have improved, use, market, offer for sale, sell, have sold, distribute, have distributed, export and import (i) peptides and their derivatives isolated during use of PROfusion Technology, including but not limited to, screening of D-Targets provided to Phylos hereunder, and (ii) Products resulting from the application of PROfusion Technology using Peptide Libraries, with or without the additional application of Cosmix Technology. The foregoing licenses to Gryphon and Affiliates to use the PROfusion Technology shall be sublicensable solely for the purpose of enabling manufacturers to produce Products, if necessary or advisable. Nothing in this Agreement shall be construed to limit Gryphon’s or its Affiliates right or ability to grant licenses in respect of Products.

 

3.3                               Gryphon shall grant Phylos and its Affiliates a fully paid up worldwide, non-exclusive license, with the right to sublicense, for any patented improvements and enhancements to Profusion Technology made by Gryphon or its Affiliates.

 

2

 

3.4                               All inventions, data, and reports resulting from the activities of Phylos under this Agreement, with the exception of improvements or enhancements to the PROfusion Technology, will be assigned to Gryphon.

 

3.5                               If a third party asserts that a patent or other right owned or controlled by it is infringed by PROfusion Technology, Phylos shall have the first right, but not the obligation, to defend against any such third party allegation of infringement by PROfusion Technology, and Phylos shall bear the costs of any such action, including attorneys’ fees. Gryphon shall also have the right to defend against such third party allegation of infringement at its own cost, if Phylos does not undertake such defense within forty-five (45) days after receiving notice of such third party allegation of infringement by the PROfusion Technology. Each Party shall promptly notify the other of its receipt from a third party of an allegation of infringement based upon the practice of any of the PROfusion Technology. For purposes of this section, the “right to defend” includes the right to commence an action for declaratory relief.

 

3.6                               If there shall be declared an interference pertaining to any part of the PROfusion Technology, Phylos shall diligently pursue such interference to conclusion and shall bear the costs thereof, including attorneys’ fees.

 

3.7                               Phylos shall obtain Gryphon’s written consent (not to be unreasonably withheld) prior to entering into any settlement or other transaction (i) with any third party to resolve such third party infringement action or assertions or (ii) to settle an interference, if such settlement or transaction does not contain a full and unconditional release of Gryphon for past infringements, if any, and a grant to Gryphon of such rights to practice third party intellectual property as shall have been granted to Phylos in such settlement., provided .however, that such consent shall not be required if such settlement or transaction contains a full and unconditional release of Gryphon for past infringement and a grant to Gryphon of such rights to practice such third party intellectual property as have been granted to Phylos in such settlement; provided, however, such consent shall not be required if such settlement or transaction contains a full and unconditional release of Gryphon for past infringement and a grant to Gryphon of such rights to practice such third party intellectual property as have been granted to Phylos in such settlement.

 

4                                                                                         Screening of Targets.

 

4.1                               Gryphon will supply at least two D-Targets to Phylos for screening , the first within 30 days and the second within 6 months of the Effective Date.

 

4.2                               Phylos will screen its PROfusion Technology peptide libraries against each D-Target, and identify the sequence of any peptides showing better than 50 nanomolar affinity for the D-Target. The Parities shall jointly agree to the libraries’ composition as part of an overall workplan to be established by the parties within 14 days of the Effective Date.

 

4.3                               Phylos will notify Gryphon of the amino acid sequences of not less than 15 and not more than 25 peptides identified pursuant to Section 4.2 above during the screening of each D-Target within ten days of their identification.

 

4.4                               The Phylos screening of the two initial D-Targets shall be deemed successful, if Phylos identifies five Products for each of the two D-Targets with affinities better than 50 nanomolar for their respective D-Targets, each Product with less than 25% sequence identity with any of the other Products relating to the same D-Target.

 

4.5                               If the Phylos screening of the two initial D-Targets is successful, then for each additional target Gryphon wishes to screen under this Agreement, it will offer the opportunity to Phylos to perform PROfusion Technology screening of Phylos Peptide Libraries against such additional targets under the same terms and conditions as pertained to the initial two D-Targets.

 

4.6                               Phylos may, in its sole discretion, accept or decline any request of Gryphon to screen more than the initial two D-Targets. Phylos must accept, if at all, in writing, any Gryphon

 

3

 

proposal of Phylos to perform additional screening within thirty days of its being sent by Gryphon to Phylos.

 

4.7                               Phylos and Gryphon will develop a work plan for each target accepted under 4.6, including project goals and timelines. Gryphon shall be precluded from applying PCT (as hereinafter defined) to any target which has been accepted for screening using PROfusion Technology by Phylos, until such time as such screening has failed to meet the goals within the timeline set forth in the work plan agreed to by the Parties.

 

4.8                               Gryphon shall compensate Phylos for its activities pursuant to Article 4 and 5 hereof at Phylos’ prevailing fully burdened FTE rate (not to exceed $ 250,000 per year for the calendar year starting January 1, 2003). In future years, but not earlier than for the calendar year starting January 1, 2005, such FTE rate can increase on Phylos’ request, but not in excess of the annual rate of inflation as measured by the Consumer Price Index for all urban areas. Such FTE charges shall not exceed by more than 20% the charges allotted therefore in the applicable mutually agreed upon work plan. Such payments shall be in addition to any sums earned by Phylos pursuant to Article 6 herein and such monthly payments shall be due at the start of each work month..

 

5                                                                                         Research Collaboration.

 

5.1                               Phylos and Gryphon will design PROfusion Technology peptide libraries adapted to the application of Cosmix Technology.

 

5.2                               The characteristics of such PROfusion Technology peptide libraries, including, but not limited to diversity, sustainability, sequence length and cloning strategies of the PROfusion library shall be agreed to by the parties and attached hereto as Exhibit C within 30 days of the Effective Date.

 

5.3                               Phylos will use its best efforts to construct the designed library according to the Work Plan and timelines agreed to by the parties and attached hereto as part of Exhibit C within 30 days following agreement of the parties pursuant to Section 5.2 above.

 

5.4                               Phylos will conduct a selection against a D-Target specified by Gryphon using the constructed libraries and will supply Gryphon with the sequence information and the appropriate DNA samples representing those selected pools. Gryphon will be free to attempt to apply Cosmix Technology to the selected pools and demonstrate the enhanced diversity contained within and increased affinity of Products developed from the resulting Cosmix Technology, if any.

 

6                                                                                         Consideration.

 

6.1                               Within 48 hours of notice of the Effective Date, Gryphon shall pay   to Phylos as a license fee.

 

6.2                               Within 48 hours of receipt of a License Approval Order (as defined below) from the U.S. Bankruptcy Court for the District of Delaware conforming to the requirements set forth below and signifying approval of this Agreement, Gryphon shall pay to Phylos the sum of   as an additional license fee. Such approval shall be by entry of a final Court order (“License Approval Order”) which is not subject to an appeal or a stay pending appeal. The inability or failure of Phylos to obtain a License Approval Order shall not affect the rights of Gryphon under this Agreement, but shall relieve Gryphon of any obligation to make payment pursuant to this Section 6.2. The License Approval Order must specifically provide that:

 

i.                                          The License Approval Order will be binding upon Phylos or any successor of Phylos or its bankruptcy estate, including but not limited to any Chapter 7 or 11 Trustee appointed in the Phylos case; and shall constitute without variation the treatment of Gryphon’s administrative claim in the Phylos case or any successor case, binding upon all parties in interest, including but not limited to in any liquidation or in any Plan of Reorganization to be confirmed by the Court or proposed by Phylos.

 

4

 

ii.                                       The License Approval Order shall provide that Gryphon will receive immediate and unconditional relief from the automatic stay to pursue its foreclosure rights without further order of the Court to enforce post-petition any of its rights under the License, including but not limited to: 1) the ability to terminate the License Agreement; 2) the ability to commence suit against Phylos or others to enforce its rights under the License Agreement; and 3) to take any other action even against property of the estate to enforce Gryphon’s rights under the license.

 

iii.                                    The rights and interests granted to Gryphon under the License Agreement shall be free and clear of all liens, security and other interests, mortgages, trust deeds, encumbrances, pledges, and claims of any kind of any party (“License Encumbrances”) whether arising on, before or after the Petition Date. All such License Encumbrances shall be terminated and released as to the License Agreement and underlying licenses and shall attach to the proceeds of the transaction in the order of priority and with the same validity, force, and effect possessed by such License Encumbrances, if any, prior to the effectiveness of the License Agreement.

 

6.3                               Upon filing of an IND or equivalent for the first indication for a Product, Gryphon will pay Phylos $50,000. If Gryphon has partnered the Product prior to filing the IND, Gryphon will pay Phylos the lesser of $250,000 or 20% of the applicable license milestone payments received to such time.

 

6.4                               Upon the start of Phase II trials (commencement of drug administration) for the first indication of a Product, Gryphon will pay Phylos $150,000. If Gryphon has partnered the Product prior to such time, Gryphon will pay Phylos the lesser of $300,000 or 20% of the applicable license milestone payments.

 

6.5                               The greater of (i) 20% of any milestones received by Gryphon from a sublicensee of a Product as a result of entry of such Product into its first pre-registration clinical trial in any Major Market (Phase III, Phase ll/lll, or an equivalent, whichever first occurs) or (ii) $2.0 million upon such event.

 

6.6                               The greater of (i) 20% of any applicable licensing milestones received by Gryphon from a sublicensee as a result of filing for the first registration (NDA or equivalent) of each Product in any Major Market, or (ii) $3.0 million upon such event.

 

6.7                               The greater of (i) 20% of any applicable licensing milestones received by Gryphon from a sublicensee as a result of the first commercial sale of each Product in any Major Market, or (ii) $5.0 million upon such event.

 

6.8                               For each Product developed hereunder by Gryphon using both PROfusion Technology and Cosmix Technology, Gryphon will pay amounts due to Phylos under Sections 6.3, 6.4, 6.5, and 6.6 at one-half the rates set forth therein in substitution of the amounts and * rates se| forth therein. Payments due Phylos under Sections 6.2 shall remain unaffected by the use of Cosmix Technology.

 

7                                                                                         Termination.

 

7.1                               Gryphon may terminate this Agreement without cause upon 60 days’ notice to Phylos.

 

7.2                               In the event of a termination of this Agreement pursuant to Section 7.1 Gryphon shall remain responsible to pay to Phylos any sums thereafter due pursuant to Article 6 above.

 

7.3                               As between Gryphon and Phylos, Gryphon shall be the sole owner of all peptides delivered hereunder and resulting Products, and its right, title, and ownership therein shall survive termination of this Agreement. Gryphon, in its sole discretion, shall be responsible for the pursuit, if any, maintenance and enforcement of any patents or other intellectual property protection relating to any such peptides or Products.

 

5

 

7.4                               The licenses granted by Phylos to Gryphon under this Agreement in respect of Products shall survive termination of this Agreement. All licenses granted hereunder by Phylos to Gryphon shall be deemed to be the grant of licenses of “Intellectual Property” under Section 365(n) of the United States Bankruptcy Code, as amended.

 

8                                                                                         Publicity.

 

Neither Party may publicize the existence of this Agreement or the participation of the other Party in the development of its Products without the express written permission of the other Party.

 

9                                                                                         Additional.

 

9.1                               Representations and Warranties. Except as disclosed on the Schedule of Exceptions attached hereto as Exhibit D, each Party represents and warrants to the other Party as of the Effective Date as follows:

 

9.1.1                     that it is duly organized, validly existing and in good standing under the laws of the jurisdiction where it is organized;

 

9.1.2                     that it is in compliance with all requirements of applicable law, except to the extent that any noncompliance would not have a material adverse effect on the properties, business, financial or other condition of such Party and would not materially adversely affect such Party’s ability to perform its obligations under this Agreement;

 

9.1.3                     that it has the lawful right to execute and perform this Agreement and to accept this grant of rights from the other Party, and that this Agreement does not violate or conflict with any other agreement to which the Party is a Party or any law or regulation applicable to it;

 

9.1.4                     that it will use the Confidential Information, Know-How, Intellectual Property, Technology, and other property of the other Party only as authorized under this Agreement, and will follow all applicable standards, specifications, laws, regulations, guidelines and rules;

 

9.1.5                     that no claim has been asserted or threatened by any person that the practice of such Party’s Technology constitutes, and to such Party’s knowledge, the practice of its Technology does not constitute, an infringement, misappropriation or violation of any intellectual property rights of any other person or constitutes unfair competition;

 

9.1.6                     that such Party shall not knowingly infringe, misappropriate or violate the intellectual property rights of any person in carrying out it obligations hereunder;

 

9.1.7                     to such Party’s knowledge, no third Party has materially infringed, misappropriated or violated, or is materially infringing, misappropriating or violating, its Technology; and

 

9.1.8                     to such Party’s knowledge, exercise by the other Party of its rights under this Agreement will not result in any infringement, misappropriation or violation of any intellectual property rights of any Third Party.

 

9.2                               Limitation. EXCEPT AS PROVIDED IN THIS ARTICLE 9, EACH PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES MAKE NO OTHER REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALUE, SAFETY, RELIABILITY, EFFICACY, NONTOXICITY, PATENTABILITY OF PATENTS OR VALID CLAIMS, ISSUED OR PENDING, NON-INFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, IN THE TECHNOLOGY, PRODUCTS OR IN ANY INTANGIBLE OR TANGIBLE ITEM GENERATED UNDER OR USED WITHIN THIS AGREEMENT;

 

6

 

9.3                               Limited Liability. IN NO EVENT SHALL EITHER PARTY TO THIS AGREEMENT BE LIABLE FOR ANY LOST PROFITS OR FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT, THE BREACH OF THIS AGREEMENT OR THE EXERCISE OF RIGHTS HEREUNDER WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY.

 

10                                                                                  Confidentiality.

 

10.1                        Definitions. In this Section 10, the following terms shall have the following meanings whenever such terms are used in their capitalized form:

 

10.1.1              “Confidential Information” means any proprietary or confidential information of the Disclosing Party, except such information falling within an exception recited below, which is communicated in any way or form by the Disclosing Party to the recipient, either before or after the Effective Date of this Agreement, and whether or not such information is identified as confidential. Confidential Information includes any data or reports provided by one Party to the other Party pursuant to this Agreement, as well as the terms and conditions of this Agreement. Confidential Information shall not include any information that:

 

a)                                     is or later becomes a part of the public domain through no fault of Recipient; 
 or

 

b)                                     recipient can demonstrate was in its rightful possession, without a restriction on use or disclosure, prior to receipt of the information from the disclosing Party or an entity acting on its behalf; or

 

c)                                      Recipient can demonstrate was rightfully received from a third party without a restriction on use or disclosure; or

 

d)                                     recipient can demonstrate by written evidence was independently developed by Recipient without use, directly or indirectly, of Confidential Information of the Disclosing Party.

 

10.1.2              “Disclosing Party” means the Party making disclosure of or otherwise communicating its Confidential Information to the other Party.

 

10.1.3              “Recipient” means the Party receiving or otherwise obtaining Confidential Information from the Disclosing Party.

 

10.1.4              “Third Party” means any party other than Gryphon, Phylos, and their respective Affiliates.

 

10.2                        Restrictions on Use. In consideration of disclosure by either of the Parties to the other Party of Confidential Information in written, oral, graphic or electronic form pursuant to the terms of this Agreement, the Recipient undertakes, unless otherwise stipulated herein, (a) to treat such Confidential Information received from the Disclosing Party with the same degree of care to maintain the secrecy of the Confidential Information as it uses to maintain the secrecy of its own information of like kind; and (b) to use the Confidential Information only to accomplish the purposes of this Agreement. Recipient will not disclose Confidential Information received from the Disclosing Party except to its employees, agents, consultants, independent contractors who have a need to know the Confidential Information in furtherance of the purposes of this Agreement (collectively, the “Representatives”), and such Representatives will be bound to Recipient by obligations of non-use and non-disclosure that are similar to or more stringent than those imposed on Recipient pursuant to this Agreement.

 

11                                                                                  Indemnification.

 

11.1                        Obligation to Indemnify. Each of the Parties hereto shall defend, indemnify and hold harmless the other Party and its Affiliates, successors and assigns, and their respective directors, officers, shareholders, partners, employees, and agents (collectively, the

 

7

 

“Indemnitees”) from and against all losses, damages, costs and expenses (including legal fees) incurred thereby or caused thereto which arise out of claims against the Indemnitees brought by Third Parties after the Effective Date of this Agreement which arise out of or relate to (i) any material breach or violation of, or failure to properly perform, any covenant or agreement made by the Indemnifying Party in this Agreement; or (ii) any material breach of any of the representations or warranties made by the Indemnifying Party in this Agreement. The Indemnifying Party shall have no obligation to indemnify any Indemnitee hereunder to the extent any such losses, damages, costs and expenses arise out of the negligence or willful misconduct of Indemnitee.

 

12                                                                                  Miscellaneous.

 

12.1                        Severability. If any court of competent jurisdiction determines that any provision of this Agreement is partially or wholly unenforceable under applicable law, such provision shall be enforced to the maximum extent permitted by applicable law, and the remaining provisions of this Agreement shall remain in full force and effect.

 

12.2                        Force Majeure. In the event that any strike, epidemic, natural disaster, fire, other act of God, war, civil disturbance, act of terrorism, explosion, or act or decision of any governmental authority renders impossible the performance of any of the obligations of the Parties or either of them under this Agreement, the Party or Parties affected shall be excused the performance of the relevant obligation or obligations upon notifying the other Party in writing, giving a detailed explanation of the occurrence in question. Upon the giving of such a notice, the performance of the Party giving notice shall be excused only to the extent and for so long as performance remains impossible. Notwithstanding the foregoing, in the event that a force majeure event declared by a Party persists for more than 180 days, the other Party shall have the right to terminate this Agreement pursuant to Section 7.1 hereof.

 

12.3                        No Assignment. Neither Party may assign this Agreement without the prior written permission of the other Party, which permission shall not be unreasonably withheld or delayed; provided, however, this Agreement may be assigned without such permission to an Affiliate or to a successor to or purchaser of all or substantially all of the business or assets of the assigning Party, or as part of a reorganization, merger, or change of control of the assigning Party.

 

12.4                        Independent Contractors. In entering into and carrying out their respective rights and obligations under this Agreement, the Parties are independent contractors and shall have no power or authority, express or implied, to bind the other Party, act on the other Party’s behalf, or in any way enter into or incur any liability for or on behalf of the other Party, and nothing in this Agreement shall be construed as giving rise to a relation of partnership or agency between the Parties.

 

12.5                        Dispute Resolution. In any disagreement or dispute that may arise between the Parties in relation to, resulting from, or arising out of this Agreement, the Parties shall attempt to settle such disagreement or dispute amicably and expeditiously by good faith negotiation. Any such dispute which cannot be so settled within ninety (90) days after the commencement of negotiations shall be referred to binding arbitration by a single, independent arbitrator who is experienced in dealing with disputes of the sort in question and with business relations of the type under this Agreement, to be appointed by mutual agreement of the Parties. If the Parties are not able to agree upon an arbitrator within thirty (30) days, each Party shall appoint one arbitrator who shall mutually agree upon a third arbitrator to serve as the arbitrator for the dispute. The arbitration will be conducted in the vicinity of the non-triggering Party in accordance with the terms and conditions of this Agreement. The arbitration shall be conducted in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The decision of the arbitrator shall be final and shall be fully and irrevocably accepted by the Parties. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator is not empowered to award treble, punitive or any other damages

 

8

 

in excess of compensatory damages, and each Party irrevocably waives any claim to recover such damages. The Parties shall use their reasonable efforts to conduct all dispute resolution procedures under this Agreement as expeditiously, efficiently and cost-effectively as possible. Notwithstanding the foregoing, any dispute relating to intellectual property or Confidential Information of either or both Parties shall not be subject to this Section 12.5 dispute resolution provision.

 

12.6                        Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Massachusetts, U.S.A. in respect of all matters, including the execution, interpretation, performance and enforcement of this Agreement.

 

12.7                        Notices. All notices and payments required or permitted by this Agreement shall be in writing and shall be sent by reliable overnight commercial courier (e.g., Federal Express, DHL, Airborne or the like), or hand delivered or mailed by registered or certified mail, postage prepaid and return receipt requested, to the relevant Party at the appropriate address, as noted below, and either Party may, in writing, change the address to which notices may be given.

 

	
If   to Gryphon:
    	
If   to PHYLOS:
    
	
 
    	
 
    
	
Gryphon   Therapeutics, Inc.
    	
PHYLOS
    
	
Gateway   Boulevard
    	
128   Spring Street
    
	
South   San Francisco, CA 94080-7014
    	
Lexington,   MA 02421
    
	
Attn:   Chief Financial Officer
    	
Attn:   CEO
    

 

12.8                        Entire Agreement; Amendment. This Agreement constitutes the entire agreement between the Parties concerning the subject matter of this Agreement, and any representation, promise or condition not incorporated in this Agreement shall not be binding upon either Party. No amendment, modification or addition to this Agreement shall be binding on the Parties unless made in writing and executed by both Parties.

 

IN WITNESS WHEREOF the Parties, by and through their authorized officers, have executed this Agreement as of the Effective Date.

 

	
 
    	
GRYPHON   THERAPEUTICS, INC.
    	
PHYLOS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   F. Blobel
    	
 
    	
By:   
    	
/s/   Gustav A. Christensen
    
	
 
    	
 
    	
Friedhelm   Blobel, Ph.D.
    	
Name:   Gustav A. Christensen
    
	
 
    	
 
    	
President   and CEO
    	
Title:   C.E.O.
    
						

 

	
 
    	
Date:   
    	
8/26/03
    	
 
    	
Date:   
    	
8/27/03
    

 

	
 
    	
Acknowledged   and agreed to:
    	
 
    
	
 
    	
/s/   B. Seed
    	
 
    	
 
    
	
 
    	
Brian   Seed
    	
 
    
				

 

	
 
    	
Date:   
    	
8/28/03
    	
 
    	
 
    

 

9

 

Exhibits:

 

A — Cosmix Technology Patents and Patent Applications

 

	
Matter No. /
    	
 
    	
 
    	
 
    	
Application No. /
    	
 
    	
 
    
	
Title
    	
 
    	
Country
    	
 
    	
Patent No.
    	
 
    	
Status
    
	
GRFN-055
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
AUSTRALIA
    	
 
    	
749249
    	
 
    	
Issued -10/3/2002
    
	
GENERATION OF DIVERSITY IN COMBINATORIAL LIBRARIES
    	
 
    	
CANADA
    	
 
    	
2279341
    	
 
    	
Pending
    
	
 
    	
CHINA
    	
 
    	
98802184.6
    	
 
    	
Pending
    
	
 
    	
 
    	
EPO
    	
 
    	
97101539.1
    	
 
    	
Pending
    
	
 
    	
 
    	
EPO
    	
 
    	
968283
    	
 
    	
Issued - 5/2/2003
    
	
 
    	
 
    	
EPO
    	
 
    	
02021507.5
    	
 
    	
Pending
    
	
 
    	
 
    	
HONG KONG
    	
 
    	
00102476.9
    	
 
    	
Pending
    
	
 
    	
 
    	
ISRAEL
    	
 
    	
131075
    	
 
    	
Pending
    
	
 
    	
 
    	
JAPAN
    	
 
    	
10.532545
    	
 
    	
Pending
    
	
 
    	
 
    	
SINGAPORE
    	
 
    	
9903327-6
    	
 
    	
Issued - 7/19/2002
    
	
 
    	
 
    	
UNITED STATES
    	
 
    	
6,310,191
    	
 
    	
Issued -10/30/2001
    
	
 
    	
 
    	
UNITED STATES
    	
 
    	
09/912,165
    	
 
    	
Pending
    
	
 
    	
 
    	
per
    	
 
    	
PCT/EP98/00533
    	
 
    	
National Stage Filed
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GRFN-056
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
EPO
    	
 
    	
02020639.7
    	
 
    	
Pending
    
	
RECOMBINATION PROCESS FOR RECOMBINING FRAGMENTS OF VARIANT   POLYNUCLEOTIDES
    	
 
    	
EPO
    	
 
    	
02021514.1
    	
 
    	
Pending
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GRFN-057
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
EPO
    	
 
    	
02016743.3
    	
 
    	
Pending
    
	
METHOD FOR GENERATING MOLECULES WITH SPECIFIC PROPERTIES BY RECOMBINATION   AND SELECTION
    	
 
    	
EPO
    	
 
    	
02027002.1
    	
 
    	
Pending
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GRFN-058
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
EPO
    	
 
    	
02023588.3
    	
 
    	
Pending
    
	
METHOD FOR MODULATING THE SURFACE CHARACTERISTICS OF A DEVICE
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

10

 

B. - Gryphon Patent Rights

 

D-ENZYME COMPOSITIONS AND METHODS OF THEIR USE

 

	
COUNTRY
    	
 
    	
REFERENCE#
    	
 
    	
TYPE
    	
 
    	
FILED
    	
 
    	
SERIAL#
    	
 
    	
ISSUED
    	
 
    	
PATENT#
    	
 
    	
STATUS
    
	
AUSTRALIA
    	
 
    	
008/00AU
    	
 
    	
DCA
    	
 
    	
6/7/1993
    	
 
    	
45996/93
    	
 
    	
10/2/1997
    	
 
    	
678768
    	
 
    	
ISSUED
    
	
AUSTRALIA
    	
 
    	
008/01AU
    	
 
    	
DIV
    	
 
    	
6/7/1993
    	
 
    	
37564/97
    	
 
    	
6/29/2000
    	
 
    	
721228
    	
 
    	
ISSUED
    
	
CANADA
    	
 
    	
008/00CA
    	
 
    	
DCA
    	
 
    	
6/7/1993
    	
 
    	
2,137,378
    	
 
    	
 
    	
 
    	
 
    	
 
    	
PENDING
    
	
EUROPEAN PATENT
    	
 
    	
008/00EP
    	
 
    	
DCA
    	
 
    	
6/7/1993
    	
 
    	
93916447.1
    	
 
    	
4/7/1999
    	
 
    	
0647266
    	
 
    	
ISSUED
    
	
EUROPEAN PATENT
    	
 
    	
008/02EP
    	
 
    	
DIV
    	
 
    	
6/7/1993
    	
 
    	
98108855.2
    	
 
    	
 
    	
 
    	
 
    	
 
    	
PENDING
    
	
JAPAN
    	
 
    	
008/00J P
    	
 
    	
DCA
    	
 
    	
6/7/1993
    	
 
    	
6-501660
    	
 
    	
 
    	
 
    	
 
    	
 
    	
PENDING
    
	
UNITED STATES
    	
 
    	
008/01 US
    	
 
    	
DCA
    	
 
    	
12/2/1994
    	
 
    	
08/343,585
    	
 
    	
4/15/2003
    	
 
    	
6,548,279
    	
 
    	
ISSUED
    
	
UNITED STATES
    	
 
    	
008/02US1
    	
 
    	
DIV
    	
 
    	
5/22/1996
    	
 
    	
08/651,144
    	
 
    	
3/21/2000
    	
 
    	
6,040,133
    	
 
    	
ISSUED
    
	
UNITED STATES
    	
 
    	
008/03US
    	
 
    	
CON
    	
 
    	
5/22/1996
    	
 
    	
08/651,303
    	
 
    	
6/8/1999
    	
 
    	
5,910.437
    	
 
    	
ISSUED
    
	
UNITED STATES
    	
 
    	
008/04US
    	
 
    	
CON
    	
 
    	
8/17/2002
    	
 
    	
10/223,103
    	
 
    	
 
    	
 
    	
 
    	
 
    	
PENDING
    
	
UNITED STATES
    	
 
    	
008/05US
    	
 
    	
CON
    	
 
    	
8/27/2002
    	
 
    	
10/229,553
    	
 
    	
 
    	
 
    	
 
    	
 
    	
PENDING
    

 

11

 

C. — PROfusion Technology Peptide Library Characteristics

 

Peptide Libraries, for the purposes of this agreement, are defined as nucleic acid libraries comprising, on each molecule:

 

· two fixed regions containing all necessary nucleic acid and amino acid encoding regions necessary for the practice of PROfusion (including but not limited to PCR primer-binding regions, a linker binding region, Transcription and Translation initiating regions, nucleic acid sequence tags, 4-8 amino acid peptide purification tags) and, optionally may include fixed amino acids, which may be cysteine, that allow the formation of a disulfide constrained loop containing the variable region, and;

 

· a variable region encoding 5-50 amino acids where at least 90%* of the amino acids encoded at each position are randomly selected from a group of at least 15 amino acids.

 

Specifically excluded from Peptide Libraries are libraries based on a naturally occurring protein or domain(s) of a protein or an de novo engineered protein designed based on the tertiary structure of naturally occurring domains, with the deliberate insertion of amino acid variability in one or more exposed portions of that molecule (Scaffolded Libraries) and libraries derived from cellular mRNA (Proteomic Libraries). Examples of scaffolded proteins already practiced are antibody VH or VL domains, the 10th Type III repeat of Fibronectin (TRINECTINTM binding proteins), Titin and Gurmarin.* Individual clones or pools for affinity maturation are exempted from the “at least 90%” restriction as long as all invariant sequences in the variable region are derived from a pre-existing clone from a peptide library.

 

12

 

Exhibit D

 

Schedule of Exceptions

 

In connection with the execution and delivery by Phylos, Inc. (“Phylos”) of that certain Research and Development Collaboration and License Agreement with Gryphon Therapeutics, Inc. (the “Agreement”), Phylos hereby provides this Schedule of Exceptions on Exhibit D. The disclosure contained herein shall qualify the Re presentations and Warranties made by Phylos in Section 9 of the Agreement.

 

United States Patent 6,361,943, Yanagawa, et al. March 26,2002. No agreement is currently in place between Phylos and Mitsubishi Chemical Corp. Phylos has filed an interference with the US Patent Office.

 

German Patent DE19646372. Pschorr, June 19, 1997. Phylos filed a brief in 5 German courts including Frankfurt and Munich.

 

Kaufman Patent Estate currently held by Advanced Molecular Evolution. Phylos has a license, but it is not transferable and may apply to the Gryphon applications if they were to take a license.

 

AME PATENT RIGHTS

 

	
Country
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    
	
United States
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
U.S.
    	
 
    	
08/349,510
    	
 
    	
12/2/94
    	
 
    	
5,723,323
    	
 
    	
3/3/98
    
	
U.S.
    	
 
    	
08/464,142
    	
 
    	
6/5/95
    	
 
    	
5,824,514
    	
 
    	
10/20/98
    
	
U.S.
    	
 
    	
08/464,327
    	
 
    	
6/5/95
    	
 
    	
5,976,862
    	
 
    	
11/2/99
    
	
U.S.
    	
 
    	
08/464,141
    	
 
    	
6/5/95
    	
 
    	
5,817,483
    	
 
    	
10/6/98
    
	
U.S.
    	
 
    	
08/468,468
    	
 
    	
6/5/95
    	
 
    	
 
    	
 
    	
 
    
	
U.S.
    	
 
    	
08/462,637
    	
 
    	
6/5/95
    	
 
    	
5,763,192
    	
 
    	
6/9/98
    
	
U.S.
    	
 
    	
08/468,477
    	
 
    	
6/5/95
    	
 
    	
5,814,476
    	
 
    	
9/29/98
    
	
U.S.
    	
 
    	
08/464,569
    	
 
    	
6/5/95
    	
 
    	
 
    	
 
    	
 
    
	
Non-U.S.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Switzerland
    	
 
    	
1379/85
    	
 
    	
3/14/86
    	
 
    	
EP 8603683
    	
 
    	
12/24/87
    
	
Switzerland
    	
 
    	
85902946.4
    	
 
    	
6/17/85
    	
 
    	
EP 229,046
    	
 
    	
5/4/94
    
	
Germany
    	
 
    	
85902946.4
    	
 
    	
6/17/85
    	
 
    	
DE 3,587,814
    	
 
    	
5/4/94
    
	
Germany
    	
 
    	
P 3546806.8
    	
 
    	
6/17/85
    	
 
    	
3,546,806
    	
 
    	
3/28/91
    
	
Germany
    	
 
    	
P 3546807.6
    	
 
    	
6/17/85
    	
 
    	
3,546,807
    	
 
    	
3/28/91
    
	
Germany
    	
 
    	
P 3590766.5
    	
 
    	
6/17/85
    	
 
    	
3,590,766
    	
 
    	
1/10/91
    
	
England
    	
 
    	
8628313.2
    	
 
    	
6/17/85
    	
 
    	
2,183,661
    	
 
    	
6/28/89
    
	
Hong Kong
    	
 
    	
9,200,202
    UK Pat 2183661
    	
 
    	
6/17/85
    	
 
    	
# 200 of 1992
    	
 
    	
6/28/95
    
	
Singapore
    	
 
    	
P 79/92
    UK Pat 2183661
    	
 
    	
6/17/85
    	
 
    	
9290079.4
    	
 
    	
6/28/95
    
	
EPO
    	
 
    	
93116225.9
    	
 
    	
6/17/85
    	
 
    	
 
    	
 
    	
 
    
	
Japan
    	
 
    	
60-502625
    	
 
    	
6/17/85
    	
 
    	
2,584,613
    	
 
    	
Published 2/26/97
    
	
Japan
    	
 
    	
7-243853
    	
 
    	
8/3/95
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
85902946.4
    	
 
    	
6/17/85
    	
 
    	
229,046
    	
 
    	
5/04/94
    
	
Canada
    	
 
    	
504,653
    	
 
    	
3/20/86
    	
 
    	
1,339,937
    	
 
    	
6/30/98
    
	
Canada
    	
 
    	
617,095
    	
 
    	
4/28/98
    	
 
    	
 
    	
 
    	
 
    

 

13

 

EXHIBIT E - Profusion Technology

 

EXHIBIT E

Phylos, Inc. Patents

 

	
Country/Type
    	
 
    	
Title
    	
 
    	
Registration/
   Application
   Number
    	
 
    	
Registration/
   Application
   Date
    	
 
    	
Status
    
	
US Provisional
    	
 
    	
IN VITRO SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
60/035,963
    	
 
    	
1/21/1997
    	
 
    	
 
    
	
US Provisional
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
60/064,491
    	
 
    	
11/6/1997
    	
 
    	
 
    
	
US
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
09/007,005
    	
 
    	
1/14/1998
    	
 
    	
Issued
    
	
PCT
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
US98/00807
    	
 
    	
1/14/1998
    	
 
    	
 
    
	
AU
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
62419/98
    	
 
    	
8/4/1999
    	
 
    	
Issued
    
	
CA
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
2278786
    	
 
    	
7/21/1999
    	
 
    	
 
    
	
CN
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
98803511.1
    	
 
    	
9/21/1999
    	
 
    	
 
    
	
EP
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
98904574.5
    	
 
    	
9/21/1999
    	
 
    	
 
    
	
HK
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
106756.1
    	
 
    	
9/21/1999
    	
 
    	
 
    
	
IL
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
131016
    	
 
    	
7/21/1999
    	
 
    	
 
    
	
IN
    	
 
    	
A PROCESS FOR THE MANUFACTURE OF A PROTEIN
    	
 
    	
158/DEL/1998
    	
 
    	
1/20/1998
    	
 
    	
 
    
	
JP
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
10-534534
    	
 
    	
7/21/1999
    	
 
    	
 
    
	
KR
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
99-7006594
    	
 
    	
7/21/1999
    	
 
    	
 
    
	
RU
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
99118585
    	
 
    	
8/20/1998
    	
 
    	
 
    
	
TH
    	
 
    	
SELECTIONS OF PROTEINS USING RNA-PROTEINS FUSIONS
    	
 
    	
41800
    	
 
    	
1/15/1998
    	
 
    	
 
    
	
TW
    	
 
    	
SELECTIONS OF PROTEINS USING RNA-PROTEINS FUSIONS
    	
 
    	
87100513
    	
 
    	
1/15/1998
    	
 
    	
 
    
	
ZA
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
98/0489
    	
 
    	
1/21/1998
    	
 
    	
 
    
	
AU
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
97069/01
    	
 
    	
8/4/1999
    	
 
    	
 
    
	
US
    	
 
    	
RNA-ANTIBODY FUSIONS AND THEIR SELECTION
    	
 
    	
09/238,710
    	
 
    	
1/28/1999
    	
 
    	
Issued
    
	
US
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
09/244,794
    	
 
    	
2/5/1999
    	
 
    	
Issued
    

 

14

 

	
US
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
09/244,796
    	
 
    	
2/5/1999
    	
 
    	
Issued
    
	
US
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
09/247,190
    	
 
    	
2/9/1999
    	
 
    	
Issued
    
	
PCT
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
US00/02589
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
AU
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
34793/00
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
CA
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
2361725
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
EP
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
913326.5
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
HK
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
02 103 482.7
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
IL
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
247,190
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
JP
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
2000-598669
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
KR
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
2001-7009987
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
NO
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
2001 3842
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
NZ
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
513153
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
RU
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
2001 124810
    	
 
    	
2/1/2000
    	
 
    	
 
    
	
US
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
09/430,049
    	
 
    	
10/29/1999
    	
 
    	
Issued
    
	
US
    	
 
    	
SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
    	
 
    	
09/876,235
    	
 
    	
6/6/2001
    	
 
    	
 
    
	
US Provisional
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
60/090,970
    	
 
    	
6/29/1998
    	
 
    	
 
    
	
US
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
09/342.980
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
PCT
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
US99/14776
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
AU
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
48470/99
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
CA
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
2,331,92
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
CN
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
99807977.4
    	
 
    	
6/29/1999
    	
 
    	
 
    

 

15

 

	
CZ
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
PV200-4564
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
EP
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
99,932,082
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
HK
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
01107096.7
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
IN
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
684
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
IL
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
140,100
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
JP
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
2000-557385
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
KR
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
2000-7014838
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
NO
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
20006675
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
NZ
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
508287
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
RU
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
2001102509
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
ZA
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
2000/7261
    	
 
    	
6/29/1999
    	
 
    	
 
    
	
US
    	
 
    	
METHODS FOR GENERATING HIGHLY DIVERSE LIBRARIES
    	
 
    	
09/434,834
    	
 
    	
11/5/1999
    	
 
    	
 
    
	
US Provisional
    	
 
    	
METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3’-UNTRANSLATED   REGIONS AND OPTIMIZING CELLULAR RNA-PROTEIN FUSION FORMATION
    	
 
    	
60/096,818
    	
 
    	
8/17/1998
    	
 
    	
 
    
	
US
    	
 
    	
METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3’-UNTRANSLATED   REGIONS AND OPTIMIZING CELLULAR RNA-PROTEIN FUSION FORMATION
    	
 
    	
09/374,962
    	
 
    	
8/16/1999
    	
 
    	
Issued
    
	
PCT
    	
 
    	
METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3’-UNTRANSLATED   REGIONS AND OPTIMIZING CELLULAR RNA-PROTEIN FUSION FORMATION
    	
 
    	
US99/18603
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
AU
    	
 
    	
METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3’-UNTRANSLATED   REGIONS AND OPTIMIZING CELLULAR RNA-PROTEIN FUSION FORMATION
    	
 
    	
54883/99
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
EP
    	
 
    	
METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3’-UNTRANSLATED   REGIONS AND OPTIMIZING CELLULAR RNA-PROTEIN FUSION FORMATION
    	
 
    	
99941179.6
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
JP
    	
 
    	
METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3’-UNTRANSLATED   REGIONS AND OPTIMIZING CELLULAR RNA-PROTEIN FUSION FORMATION
    	
 
    	
2000-565171
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
CA
    	
 
    	
METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3’-UNTRANSLATED   REGIONS AND OPTIMIZING CELLULAR RNA PROTEIN FUSION FORNATION
    	
 
    	
2,334,946
    	
 
    	
8/16/1999
    	
 
    	
 
    

 

16

 

	
US
    	
 
    	
METHODS FOR PRODUCING NUCLEIC ACIDS LACKING 3’-UNTRANSLATED   REGIONS AND OPTIMIZING CELLULAR RNA-PROTEIN FUSION FORMATION
    	
 
    	
09/910,518
    	
 
    	
7/20/2001
    	
 
    	
 
    
	
US Provisional
    	
 
    	
IDENTIFICATION OF COMPOUND-PROTEIN INTERACTIONS USING LIBRARIES   OF PROTEIN-NUCLEIC ACID FUSION MOLECULES
    	
 
    	
60/096,820
    	
 
    	
8/17/1998
    	
 
    	
 
    
	
US
    	
 
    	
IDENTIFICATION OF COMPOUND-PROTEIN INTERACTIONS USING LIBRARIES   OF PROTEIN-NUCLEIC ACID FUSION MOLECULES
    	
 
    	
09/374,964
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
PCT
    	
 
    	
IDENTIFICATION OF COMPOUND-PROTEIN INTERACTIONS USING LIBRARIES   OF PROTEIN-NUCLEIC ACID FUSION MOLECULES
    	
 
    	
US99/18600
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
AU
    	
 
    	
IDENTIFICATION OF COMPOUND-PROTEIN INTERACTIONS USING LIBRARIES   OF PROTEIN-NUCLEIC ACID FUSION MOLECULES
    	
 
    	
61296/99
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
CA
    	
 
    	
IDENTIFICATION OF COMPOUND-PROTEIN INTERACTIONS USING LIBRARIES   OF PROTEIN-NUCLEIC ACID FUSION MOLECULES
    	
 
    	
2,337,490
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
EP
    	
 
    	
IDENTIFICATION OF COMPOUND-PROTEIN INTERACTIONS USING LIBRARIES   OF PROTEIN-NUCLEIC ACID FUSION MOLECULES
    	
 
    	
999480.42.9
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
JP
    	
 
    	
IDENTIFICATION OF COMPOUND-PROTEIN INTERACTIONS USING LIBRARIES   OF PROTEIN-NUCLEIC ACID FUSION MOLECULES
    	
 
    	
2000-564919
    	
 
    	
8/16/1999
    	
 
    	
 
    
	
US Provisional
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
60/110,549
    	
 
    	
12/2/1998
    	
 
    	
 
    
	
US
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
09/453,190
    	
 
    	
12/2/1999
    	
 
    	
Issued
    
	
PCT
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
US99/28472
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
AU
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
23509/00
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
CA
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
2350417
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
EP
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
99967171.2
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
HK
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
02100680.3
    	
 
    	
1/29/2002
    	
 
    	
 
    
	
IL
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
143236
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
IN
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
 
    	
 
    	
12/2/1999
    	
 
    	
 
    

 

17

 

	
JP
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
2000-585,454
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
KR
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
2001-7006742
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
NO
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
2001-2735
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
NZ
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
511699
    	
 
    	
12/2/1999
    	
 
    	
 
    
	
US
    	
 
    	
DNA-PROTEIN FUSIONS AND USES THEREOF
    	
 
    	
10/180,819
    	
 
    	
6/26/2002
    	
 
    	
 
    
	
US Provisional
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
60/137,032
    	
 
    	
6/1/1999
    	
 
    	
 
    
	
US
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
09/585,207
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
PCT
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
US00/15077
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
AU
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
54555/00
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
CA
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
2,373,047
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
EP
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
939 474.3
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
HK
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
02105898.0
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
JP
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
2000-620978
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
NO
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
2001 5828
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
NZ
    	
 
    	
METHODS OF PRODUCING 5’-NUCLEIC ACID-PROTEIN CONJUGATES
    	
 
    	
514772
    	
 
    	
6/1/2000
    	
 
    	
 
    
	
US Provisional
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
60/143,339
    	
 
    	
7/12/1999
    	
 
    	
 
    
	
US
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
09/614,264
    	
 
    	
7/12/2000
    	
 
    	
 
    
	
PCT
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
US00/40347
    	
 
    	
7/11/2000
    	
 
    	
 
    
	
AU
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
71338/00
    	
 
    	
7/11/2000
    	
 
    	
 
    
	
CA
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
2,372,795
    	
 
    	
7/11/2000
    	
 
    	
 
    
	
EP
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
960 132.S
    	
 
    	
7/11/2000
    	
 
    	
 
    
	
HK
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
02106434.S
    	
 
    	
7/11/2000
    	
 
    	
 
    
	
IL
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
146451
    	
 
    	
7/11/2000
    	
 
    	
 
    
	
NZ
    	
 
    	
C-TERMINAL PROTEIN TAGGING
    	
 
    	
515292
    	
 
    	
7/11/2000
    	
 
    	
 
    
	
US Provisional
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
60/145,834
    	
 
    	
7/27/1999
    	
 
    	
 
    

 

18

 

	
US
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
09/619,103
    	
 
    	
7/19/2000
    	
 
    	
Issued
    
	
PCT
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
US00/19653
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
AU
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
61112/00
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
CA
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
2,377,468
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
EP
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
947 524.5
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
HK
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
2106728.4
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
IL
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
147037
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
JP
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
2001-512922
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
KR
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
2002-7001058
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
NO
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
2002 0348
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
NZ
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
516055
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
RU
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
2002104938
    	
 
    	
7/19/2000
    	
 
    	
 
    
	
US
    	
 
    	
PEPTIDE ACCEPTOR LIGATION METHODS
    	
 
    	
10/208,357
    	
 
    	
7/30/2002
    	
 
    	
 
    
	
US Provisional
    	
 
    	
METHODS FOR ENCODING & SORTING IN VITRO TRANSLATED   PROTEINS
    	
 
    	
60/151,261
    	
 
    	
8/27/1999
    	
 
    	
 
    
	
US
    	
 
    	
METHODS FOR ENCODING & SORTING IN VITRO TRANSLATED   PROTEINS
    	
 
    	
09/648,040
    	
 
    	
8/25/2000
    	
 
    	
Issued
    
	
PCT
    	
 
    	
METHODS FOR ENCODING & SORTING IN VITRO TRANSLATED   PROTEINS
    	
 
    	
US00/23414
    	
 
    	
8/25/2000
    	
 
    	
 
    
	
AU
    	
 
    	
METHODS FOR ENCODING & SORTING IN VITRO TRANSLATED   PROTEINS
    	
 
    	
69387/00
    	
 
    	
8/25/2000
    	
 
    	
 
    
	
CA
    	
 
    	
METHODS FOR ENCODING & SORTING IN VITRO TRANSLATED   PROTEINS
    	
 
    	
2382545
    	
 
    	
8/25/2000
    	
 
    	
 
    
	
EP
    	
 
    	
METHODS FOR ENCODING & SORTING IN VITRO TRANSLATED   PROTEINS
    	
 
    	
00 957 818.8
    	
 
    	
8/25/2000
    	
 
    	
 
    
	
JP
    	
 
    	
METHODS FOR ENCODING & SORTING IN VITRO TRANSLATED   PROTEINS
    	
 
    	
2001-520897
    	
 
    	
8/25/2000
    	
 
    	
 
    
	
US
    	
 
    	
METHODS FOR ENCODING & SORTING IN VITRO TRANSLATED   PROTEINS
    	
 
    	
10/217,914
    	
 
    	
8/13/2002
    	
 
    	
 
    
	
US
    	
 
    	
COUPLED ISOTHERMAL POLYNUCLEOTIDE AMPLIFICATION AND TRANSLATION   SYSTEM
    	
 
    	
07/939,302
    	
 
    	
9/2/1992
    	
 
    	
 
    
	
US
    	
 
    	
COUPLED ISOTHERMAL POLYNUCLEOTIDE AMPLIFICATION AND TRANSLATION   SYSTEM
    	
 
    	
08/231,587
    	
 
    	
4/20/1994
    	
 
    	
 
    
	
AT
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
BE
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
CH
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
DE
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    

 

19

 

	
EP
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
ES
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
FR
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
GB
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
GR
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
IT
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
LU
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
NL
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
SE
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
EP0341444
    	
 
    	
4/13/1989
    	
 
    	
Issued
    
	
US
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
07/842,465
    	
 
    	
2/27/1992
    	
 
    	
Issued
    
	
US
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
08/320,663
    	
 
    	
10/11/1994
    	
 
    	
Issued
    
	
US
    	
 
    	
RAPID MUTATIONAL ANALYSIS METHOD
    	
 
    	
09/400,207
    	
 
    	
9/21/1999
    	
 
    	
 
    
	
US
    	
 
    	
SYSTEMIC POLYPEPTIDE EVOLUTION BY REVERSE TRANSCRIPTION
    	
 
    	
07/829,461
    	
 
    	
1/31/1992
    	
 
    	
Issued
    
	
US
    	
 
    	
SYSTEMIC POLYPEPTIDE EVOLUTION BY REVERSE TRANSCRIPTION
    	
 
    	
09/197,649
    	
 
    	
11/23/1998
    	
 
    	
Issued
    
	
US
    	
 
    	
SYSTEMIC POLYPEPTIDE EVOLUTION BY REVERSE TRANSCRIPTION
    	
 
    	
09/790,399
    	
 
    	
2/22/2001
    	
 
    	
 
    
	
US Provisional
    	
 
    	
SCREENING AND AFFINITY BINDING ASSAYS
    	
 
    	
60/275,197
    	
 
    	
3/12/2001
    	
 
    	
 
    
	
US Provisional
    	
 
    	
IN VITRO PROTEIN INTERACTION DETECTION SYSTEMS
    	
 
    	
60/300,267
    	
 
    	
6/21/2001
    	
 
    	
 
    
	
US
    	
 
    	
IN VITRO PROTEIN INTERACTION DETECTION SYSTEMS
    	
 
    	
10/176,826
    	
 
    	
6/20/2002
    	
 
    	
 
    
	
PCT
    	
 
    	
IN VITRO PROTEIN INTERACTION DETECTION SYSTEMS
    	
 
    	
US02/19937
    	
 
    	
6/20/2002
    	
 
    	
 
    
	
US Provisional
    	
 
    	
MODULAR ASSEMBLY OF NUCLEIC ACID-PROTEIN FUSION MOLECULES
    	
 
    	
60/309,231
    	
 
    	
7/31/2001
    	
 
    	
 
    
	
US
    	
 
    	
MODULAR ASSEMBLY OF NUCLEIC ACID-PROTEIN FUSION MOLECULES
    	
 
    	
10/
    	
 
    	
7/31/2002
    	
 
    	
 
    
	
PCT
    	
 
    	
MODULAR ASSEMBLY OF NUCLEIC ACID-PROTEIN FUSION MOLECULES
    	
 
    	
US02/24180
    	
 
    	
7/31/2002
    	
 
    	
 
    
	
US Provisional
    	
 
    	
CELLULAR KINASE TARGETS AND INHIBITORS AND METHODS FOR THEIR USE
    	
 
    	
60/337,990
    	
 
    	
11/13/2001
    	
 
    	
 
    
	
US
    	
 
    	
CELLULAR KINASE TARGETS AND INHIBITORS AND METHODS FOR THEIR USE
    	
 
    	
10/293,086
    	
 
    	
11/13/2002
    	
 
    	
 
    
	
US Provisional
    	
 
    	
SOLID PHASE IMMOBILIZATION OF PROTEINS AND PEPTIDES
    	
 
    	
60/333,470
    	
 
    	
11/27/2001
    	
 
    	
 
    
	
US
    	
 
    	
SOLID PHASE IMMOBILIZATION OF PROTEINS AND PEPTIDES
    	
 
    	
10/302,456
    	
 
    	
11/21/2002
    	
 
    	
 
    

 

20

 

	
de
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS,   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
199 23 966.5
    	
 
    	
5/25/1999
    	
 
    	
 
    
	
PCT
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS,   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
PCT/EP00/04791
    	
 
    	
5/25/2000
    	
 
    	
 
    
	
CA
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS.   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
2,374,438
    	
 
    	
5/25/2000
    	
 
    	
 
    
	
CN
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS,   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
00809231.1
    	
 
    	
5/25/2000
    	
 
    	
 
    
	
CZ
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS,   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
PV2001-4201
    	
 
    	
5/25/2000
    	
 
    	
 
    
	
EE
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS,   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
0616/01 PC
    	
 
    	
5/25/2000
    	
 
    	
 
    
	
EP
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS,   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
941987
    	
 
    	
5/25/2000
    	
 
    	
 
    
	
IL
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS.   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
146371
    	
 
    	
5/25/2000
    	
 
    	
 
    
	
JP
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS,   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
2000-620126
    	
 
    	
5/25/2000
    	
 
    	
 
    
	
US
    	
 
    	
DETECTION SYSTEM FOR ANALYZING MOLECULAR INTERACTIONS.   PRODUCTION AND UTILIZATION THEREOF
    	
 
    	
5/25/2000
    	
 
    	
 
    	
 
    	
 
    
	
de
    	
 
    	
TEST SYSTEM FOR DETECTING ANALYTES, A METHOD FOR THE PRODUCTION   THEREOF AND ITS USE
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
TEST SYSTEM FOR DETECTING ANALYTES, A METHOD FOR THE PRODUCTION   THEREOF AND ITS USE
    	
 
    	
PCT/EP00/10336
    	
 
    	
10/20/2000
    	
 
    	
 
    
	
CA
    	
 
    	
TEST SYSTEM FOR DETECTING ANALYTES, A METHOD FOR THE PRODUCTION   THEREOF AND ITS USE
    	
 
    	
2393703
    	
 
    	
10/20/2000
    	
 
    	
 
    
	
de
    	
 
    	
BIO-PROBES AND USES THEREOF
    	
 
    	
100 33 194.7
    	
 
    	
6/26/2001
    	
 
    	
 
    
	
PCT
    	
 
    	
BIO-PROBES AND USES THEREOF
    	
 
    	
PCT/EP01/07259
    	
 
    	
6/26/2001
    	
 
    	
 
    
	
de
    	
 
    	
METHODS FOR IDENTIFYING SPECIFICALLY CLEAVABLE PEPTIDES AND USE   OF SUCH PEPTIDE SEQUENCES
    	
 
    	
100 41 238
    	
 
    	
8/22/2000
    	
 
    	
 
    
	
PCT
    	
 
    	
METHODS FOR IDENTIFYING SPECIFICALLY CLEAVABLE PEPTIDES AND USE   OF SUCH PEPTIDE SEQUENCES
    	
 
    	
PCT/EP01/0910
    	
 
    	
8/7/2001
    	
 
    	
 
    
	
de
    	
 
    	
METHOD FOR ISOLATING AND IDENTIFYING EFFECTORS
    	
 
    	
199 59 857
    	
 
    	
 
    	
 
    	
 
    

 

21

 

	
PCT
    	
 
    	
METHOD FOR ISOLATING AND IDENTIFYING EFFECTORS
    	
 
    	
PCT/EP01/14337
    	
 
    	
12/6/2001
    	
 
    	
 
    
	
de
    	
 
    	
SECRETION SIGNAL PEPTIDES, DNA SEQUENCES THEREOF, EXPRESSION   VECTORS PREPARABLE THEREWITH FOR EUKARYOTIC CELLS AND USE THEREOF FOR   BIOTECHNOLOGICAL PREPARATION OF PROTEINS
    	
 
    	
100 62 302.6
    	
 
    	
12/14/2000
    	
 
    	
 
    
	
de
    	
 
    	
PEPTIDE ACCEPTOR /tRNA-HYBRID MOLECULE AND ITS USE FOR PREPARING   CODON-SPECIFICALLY ARRESTED TRANSLATION COMPLEXES
    	
 
    	
101 16 585.4
    	
 
    	
4/3/2001
    	
 
    	
 
    
	
PCT
    	
 
    	
PEPTIDE ACCEPTOR /tRNA-HYBRID MOLECULE AND ITS USE FOR PREPARING   CODON-SPECIFICALLY ARRESTED TRANSLATION COMPLEXES
    	
 
    	
PCT/EP02/03649
    	
 
    	
4/3/2002
    	
 
    	
 
    
	
US Provisional
    	
 
    	
NOVEL METHOD FOR CLONING VARIABLE DOMAIN SEQUENCES OF   IMMUNOLOGICAL GENE REPERTOIRE
    	
 
    	
60/290,907
    	
 
    	
5/14/2001
    	
 
    	
 
    
	
PCT
    	
 
    	
NOVEL METHOD FOR CLONING VARIABLE DOMAIN SEQUENCES OF   IMMUNOLOGICAL GENE REPERTOIRE
    	
 
    	
US/02/15125
    	
 
    	
5/14/2002
    	
 
    	
 
    

 

22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]